Targeted depletion of non-targeted library molecules using poison primers during targeted capture of next-generation sequencing libraries

The use of poison primers in nucleic acid enrichment techniques addresses mispriming and ribosome depletion issues, improving on-target rates and reducing sequencing waste by preventing non-target capture and eliminating the need for costly ribosome depletion.

JP7587013B2Active Publication Date: 2024-11-19F HOFFMANN LA ROCHE & CO AG +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023500275
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-07-08
Filing Date
2021-07-07
Publication Date
2024-11-19
Estimated Expiration
2041-07-07

AI Technical Summary

Technical Problem

Current nucleic acid enrichment techniques face challenges such as low on-target rates and complex workflows in hybridization-based capture, and high off-target sequencing in amplification-based capture, with mispriming and ribosome depletion being time-consuming and expensive.

Method used

Incorporation of poison primers during hybridization and extension steps to prevent mispriming and reduce the need for ribosome depletion, using a method that includes target capture primers with capture moieties and poison primers without, which are designed to hybridize and extend on non-target molecules to prevent capture.

Benefits of technology

This approach enhances on-target rates, reduces sequencing waste, and eliminates the need for costly and time-consuming ribosome depletion, effectively enriching low-abundance target nucleic acids like mRNA and fusion transcripts.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587013000001
    Figure 0007587013000001
  • Figure 0007587013000002
    Figure 0007587013000002
  • Figure 0007587013000003
    Figure 0007587013000003
Patent Text Reader

Abstract

The present disclosure relates to compositions, kits, and methods for target enrichment by unidirectional primer extension, which utilize both poison primers and target capture primers.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Background of the disclosure In many nucleic acid enrichment techniques, it may be useful to first provide a "shotgun library" of nucleic acid molecules, whereby longer nucleic acid sequences derived from a sample are subdivided into smaller fragments that are compatible with short-read sequencing technologies (i.e., approximately 50-500 nucleotides). To prepare a shotgun library, high molecular weight nucleic acid strands (typically cDNA or genomic DNA) are sheared into random fragments, optionally modified by ligation of common end sequences (i.e., adapters), and size-selected for downstream processing and analysis. For example, it may be useful to selectively capture a subset of nucleic acids within a shotgun library.

[0002] Currently, there are two general categories of capture technologies: hybridization-based capture and amplification-based capture. Hybridization-based capture methods offer the advantage of allowing the recovery of the entire original shotgun library fragments, as opposed to replicating and recovering only a subset of the original library fragments. However, the on-target rate associated with hybridization-based capture is generally lower compared to amplification-based methods. In particular, the lower on-target rate results in wasted sequencing capacity, as off-target capture products must be sequenced. Furthermore, the workflow associated with hybridization-based capture methods can be complicated with long turnaround times compared to amplification-based approaches. In contrast, amplification-based approaches such as anchored multiplex PCR methods offer the advantages of simple workflows, faster turnaround times, and higher on-target rates compared to hybridization-based methods, but some drawbacks remain. For example, the target capture primer sequences incorporated into the library fragments after amplification result in wasted sequencing capacity. Furthermore, the library fragments do not necessarily represent the original shotgun library, as the template is necessarily cleaved at the target-specific primer binding site.

[0003] In some embodiments, the shotgun target capture technique involves hybridization and extension of a biotinylated primer. In some embodiments, this is followed by target enrichment using streptavidin-linked magnetic beads. In some embodiments, the bound target library fragments can be released from the streptavidin using a non-biotinylated target release primer or directly amplified from the streptavidin beads (see, e.g., U.S. Patent Application Publication Nos. 2020 / 0032244 and 2018 / 0016630, the disclosures of which are incorporated herein by reference in their entirety). However, in some embodiments, the target capture primer may misprime, thus capturing and enriching undesired library molecules, which may be amplified and sequenced downstream. This could be problematic (i) when the abundance of undesired molecules far exceeds that of the target molecules (e.g., high abundance of ribosomal RNA (rRNA)-derived molecules in a cDNA library, since cDNA libraries typically contain about 95% rRNA and about 5% mRNA-derived molecules) and / or (ii) when the abundance of a particular fusion transcript is low compared to the wild-type transcript, making it difficult to detect.

[0004] Depletion of undesired library molecules is a recurring theme when preparing and analyzing next generation sequencing libraries. For example, rRNA comprises at least 90% of the total RNA extracted from mammalian tissue or cell line samples. Informative transcriptional profiling using massively parallel sequencing techniques requires either enrichment of mature poly-adenylated transcripts or targeted depletion of the rRNA fraction. Ribosome depletion is a transcriptomics technique that allows efficient detection of functionally relevant coding and non-coding transcripts by removal of highly abundant rRNA species. Ribosome depletion, as performed prior to cDNA synthesis, is considered to be time consuming and / or expensive. Summary of the Invention

[0005] A brief summary of disclosures It is desirable to reduce mispriming events during the hybridization and extension steps of shotgun capture. It is also desirable to avoid the use of time-consuming and expensive rRNA depletion methods. In some embodiments, the present disclosure provides a modified shotgun target capture approach in which a poison primer is included with the target capture primer during any hybridization and extension steps. It is believed that the inclusion of a poison primer that does not include a capture moiety compared to the target capture primer can prevent or reduce the mispriming and off-target effects that are often observed during target enrichment. It is further believed that the method of the present disclosure of introducing a poison primer with the target capture primer avoids the need for time-consuming rRNA removal methods, such as ribosome depletion, while still facilitating rRNA depletion during the capture and enrichment steps. Furthermore, it is believed that the method of the present disclosure can reduce the sequencing depth required to detect desired target nucleic acid sequences.

[0006] One aspect of the present disclosure is a method of enriching at least one target nucleic acid molecule in a library of nucleic acid molecules, comprising hybridizing a first target capture primer to a first target nucleic acid molecule in the library of nucleic acid molecules, wherein the first target capture primer comprises a capture portion; and hybridizing a first poison primer to a first non-target nucleic acid molecule in the library of nucleic acid molecules, wherein the first poison primer does not comprise a capture portion. and extending both the hybridized first target capture primer and the hybridized first poison primer, where the extension of the hybridized first target capture primer provides a first target capture primer extension complex comprising the first target nucleic acid molecule and the extended first target capture primer; and enriching the first target nucleic acid molecule in a library of nucleic acid molecules relative to the library of nucleic acid molecules. In some embodiments, the first target capture primer and the first poison primer are added to the library as a pool of primers. In some embodiments, each of the nucleic acid molecules in the library of nucleic acid molecules comprises a first end comprising a first adaptor and a second end comprising a second adaptor. In some embodiments, the method does not comprise performing a ribosome depletion step.

[0007] In some embodiments, extension of the hybridized first poison primer prevents or reduces hybridization of the first target capture primer to the first non-target nucleic acid molecule, i.e., extension of the hybridized first poison primer prevents or reduces mispriming. In other embodiments, extension of the hybridized first poison primer displaces the first target primer hybridized to the first non-target nucleic acid molecule, i.e., extension of the first hybridized poison primer displaces the first target primer misprimed to the first non-target nucleic acid molecule.

[0008] In some embodiments, the method further comprises amplifying the first target nucleic acid molecule with a first amplification primer and a second amplification primer, the first amplification primer comprising a 3' end complementary to the first adaptor and the second amplification primer comprising a 3' end complementary to the second adaptor. In some embodiments, the method further comprises sequencing the amplified target nucleic acid molecule.

[0009] In some embodiments, enriching the first target nucleic acid molecule relative to the library of nucleic acid molecules comprises (i) capturing the first target capture primer extension complex, (i) removing non-captured non-target nucleic acid molecules, and (ii) releasing the first target nucleic acid molecule from the captured first target capture primer extension complex. In some embodiments, capturing the first target capture primer extension complex comprises contacting the first target capture primer extension complex with a functionalized substrate.

[0010] In some embodiments, the capture portion of the first target capture primer comprises a first member of a pair of specific binding entities and the functionalized substrate comprises a second member of the pair of specific binding entities. In some embodiments, the first member of the pair of specific binding entities is selected from the group consisting of biotin, an antigenic molecule, an enzyme substrate, a receptor ligand, a polysaccharide, a thiolated molecule, and an amine-terminated molecule. In some embodiments, the second member of the pair of specific binding entities is selected from the group consisting of streptavidin, an antibody, an enzyme, a receptor, a lectin, a gold particle, and an NHS-activated moiety. In some embodiments, the capture portion of the first target capture primer comprises biotin. In some embodiments, the functionalized surface comprises streptavidin. In some embodiments, the functionalized substrate comprises a bead having a surface functionalized with the second member of the pair of specific binding entities. In some embodiments, the functionalized substrate comprises a bead having a surface comprising a plurality of streptavidin molecules.

[0011] In some embodiments, the first target capture primer is attached to the substrate via the capture moiety prior to hybridization of the first target capture primer to a first target nucleic acid molecule in a library of nucleic acid molecules, in some embodiments, the first target nucleic acid molecule is captured to the substrate by hybridization of the first target capture primer to the first target nucleic acid molecule and / or extension of the hybridized first target capture primer.

[0012] In some embodiments, capturing the first target capture primer extension complex comprises: (i) hybridizing a universal capture oligonucleotide to the capture portion of the first target capture primer extension complex to form a universal capture oligonucleotide complex, where the universal capture oligonucleotide comprises (a) a first member of a pair of specific binding entities and (b) a nucleotide sequence complementary to at least a portion of the capture sequence of the capture portion; and (ii) contacting the universal capture complex with a functionalized substrate, where the functionalized substrate comprises a second member of the pair of specific binding entities.

[0013] In some embodiments, removing the non-captured nucleic acid molecules comprises washing away the non-captured non-target nucleic acid molecules. In some embodiments, releasing the captured first target capture primer extension complex comprises: (i) hybridizing a release primer to the first target nucleic acid molecule; and (b) extending the hybridized release primer. In some embodiments, the hybridized first target capture primer is extended by a first polymerase, and the hybridized release primer is extended by a second polymerase. In some embodiments, the first polymerase and the second polymerase are different. In some embodiments, the first target capture primer has a melting temperature higher than the melting temperature of the first poison primer.

[0014] In some embodiments, the library of nucleic acid molecules comprises a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules, and the plurality of target nucleic acid molecules are low in abundance compared to the plurality of non-target nucleic acid molecules. In some embodiments, the plurality of target nucleic acid molecules comprises less than about 10% of the nucleic acid molecules in the library of nucleic acid molecules. In some embodiments, the plurality of target nucleic acid molecules comprises less than about 5% of the nucleic acid molecules in the library of nucleic acid molecules. In some embodiments, the plurality of target nucleic acid molecules comprises mRNA-derived nucleic acid molecules. In some embodiments, the plurality of target nucleic acid molecules comprises fusion transcripts.

[0015] Another aspect of the disclosure is a kit comprising a first target capture primer that is complementary to a target nucleic acid molecule in a library of nucleic acid molecules and comprises a capture moiety, and a first poison primer that is complementary to a non-target nucleic acid molecule in the library of nucleic acid molecules and does not comprise a capture moiety. In some embodiments, the first target capture primer has a Tm in the range of about 55° C. to about 65° C. In some embodiments, the first poison primer has a Tm in the range of about 65° C. to about 68° C. In some embodiments, the kit further comprises at least one polymerase. In some embodiments, the kit further comprises at least two different polymerases. In some embodiments, the kit further comprises a plurality of nucleotides. In some embodiments, the kit further comprises one or more buffers and / or wash solutions. In some embodiments, the kit further comprises beads having a functionalized surface. In some embodiments, the kit further comprises one or more release primers. In some embodiments, the kit further comprises first and second amplification primers.

[0016] Another aspect of the disclosure is a composition comprising a nucleic acid molecule library comprising a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules, the plurality of target nucleic acid molecules being in low abundance relative to the plurality of non-target nucleic acid molecules; a first target capture primer that is complementary to a first target nucleic acid molecule in the library of nucleic acid molecules and comprises a capture moiety; a first poison primer that is complementary to a first non-target nucleic acid molecule in the library of nucleic acid molecules and does not comprise a capture moiety; and a first polymerase. In some embodiments, the composition further comprises a second polymerase that is different from the first polymerase. In some embodiments, the composition further comprises a functionalized substrate. In some embodiments, the composition further comprises one or more adapter molecules. In some embodiments, the composition further comprises one or more release primers. In some embodiments, the composition further comprises first and second amplification primers.

[0017] Another aspect of the present disclosure is a composition comprising: a nucleic acid molecule library comprising a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules; a first target capture primer hybridized to a portion of a first target nucleic acid molecule in the library of nucleic acid molecules, the first target capture primer comprising a capture portion bound to a functionalized substrate; and a first poison primer hybridized to a portion of a first non-target nucleic acid molecule in the library of nucleic acid molecules, the first poison primer not comprising a capture portion. In some embodiments, the plurality of target nucleic acid molecules are low abundance compared to the plurality of non-target nucleic acid molecules.

[0018] In some embodiments, the capture moiety comprises a first member of a pair of specific binding entities. In some embodiments, the functionalized substrate is a bead having a surface functionalized with a second member of the pair of specific binding entities. In some embodiments, the first member of the pair of specific binding entities is selected from the group consisting of biotin, an antigenic molecule, an enzyme substrate, a receptor ligand, a polysaccharide, a thiolated molecule, and an amine-terminated molecule. In some embodiments, the second member of the pair of specific binding entities is selected from the group consisting of streptavidin, an antibody, an enzyme, a receptor, a lectin, a gold particle, and an NHS-activated moiety. In some embodiments, the capture moiety of the first target capture primer comprises biotin. In some embodiments, the functionalized surface comprises streptavidin.

[0019] Another aspect of the disclosure is a composition enriched for a target nucleic acid molecule, the composition being prepared by: (i) hybridizing a first target capture primer to a first target nucleic acid molecule in a library of nucleic acid molecules, the library of nucleic acid molecules comprising a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules, the plurality of target nucleic acid molecules being in low abundance relative to the plurality of non-target nucleic acid molecules, the first target capture primer comprising a capture moiety; and (ii) hybridizing a first poison primer to a first non-target nucleic acid molecule in the library of nucleic acid molecules, the first poison primer comprising a capture moiety. (iii) extending both the hybridized first target capture primer and the hybridized first poison primer, where the extension of the hybridized first target capture primer provides a first target capture primer extension complex comprising the first target nucleic acid molecule and the extended first target capture primer; and (iv) enriching the first target nucleic acid molecule in the library of nucleic acid molecules relative to the library of nucleic acid molecules.

[0020] In some embodiments, the composition is enriched for low abundance fusion transcripts. In some embodiments, the composition is enriched for mRNA-derived molecules. In some embodiments, the composition enriched for target nucleic acid molecules is prepared without a ribosome depletion step.

[0021] In some embodiments, the first target capture primer and the first poison primer are added to the library as a pool of primers. In some embodiments, each of the nucleic acid molecules in the library of nucleic acid molecules comprises a first end that includes a first adaptor and a second end that includes a second adaptor.

[0022] In some embodiments, the method further comprises amplifying the first target nucleic acid molecule with a first amplification primer and a second amplification primer, the first amplification primer comprising a 3' end complementary to the first adaptor and the second amplification primer comprising a 3' end complementary to the second adaptor. In some embodiments, the method further comprises sequencing the amplified target nucleic acid molecule.

[0023] In some embodiments, enriching the first target nucleic acid molecule relative to the library of nucleic acid molecules comprises (i) capturing the first target capture primer extension complex, (i) removing non-captured non-target nucleic acid molecules, and (ii) releasing the first target nucleic acid molecule from the captured first target capture primer extension complex. In some embodiments, capturing the first target capture primer extension complex comprises contacting the first target capture primer extension complex with a functionalized substrate.

[0024] In some embodiments, the capture portion of the first target capture primer comprises a first member of a pair of specific binding entities and the functionalized substrate comprises a second member of the pair of specific binding entities. In some embodiments, the first member of the pair of specific binding entities is selected from the group consisting of biotin, an antigenic molecule, an enzyme substrate, a receptor ligand, a polysaccharide, a thiolated molecule, and an amine-terminated molecule. In some embodiments, the second member of the pair of specific binding entities is selected from the group consisting of streptavidin, an antibody, an enzyme, a receptor, a lectin, a gold particle, and an NHS-activated moiety. In some embodiments, the capture portion of the first target capture primer comprises biotin. In some embodiments, the functionalized surface comprises streptavidin. In some embodiments, the functionalized substrate comprises a bead having a surface functionalized with the second member of the pair of specific binding entities. In some embodiments, the functionalized substrate comprises a bead having a surface comprising a plurality of streptavidin molecules.

[0025] In some embodiments, the first target capture primer is attached to the substrate via the capture moiety prior to hybridization of the first target capture primer to a first target nucleic acid molecule in a library of nucleic acid molecules, in some embodiments, the first target nucleic acid molecule is captured to the substrate by hybridization of the first target capture primer to the first target nucleic acid molecule and / or extension of the hybridized first target capture primer.

[0026] In some embodiments, capturing the first target capture primer extension complex comprises: (i) hybridizing a universal capture oligonucleotide to the capture portion of the first target capture primer extension complex to form a universal capture oligonucleotide complex, where the universal capture oligonucleotide comprises (a) a first member of a pair of specific binding entities and (b) a nucleotide sequence complementary to at least a portion of the capture sequence of the capture portion; and (ii) contacting the universal capture complex with a functionalized substrate, where the functionalized substrate comprises a second member of the pair of specific binding entities.

[0027] In some embodiments, removing the non-captured nucleic acid molecules comprises washing away the non-captured non-target nucleic acid molecules. In some embodiments, releasing the captured first target capture primer extension complex comprises: (i) hybridizing a release primer to the first target nucleic acid molecule, and (b) extending the hybridized release primer. In some embodiments, the hybridized first target capture primer is extended by a first polymerase, and the hybridized release primer is extended by a second polymerase. [Brief description of the drawings]

[0028] For a general understanding of the features of the present disclosure, reference is made to the drawings, in which like reference numerals are used throughout to identify identical elements. The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.

[0029] [Figure 1A]Provides an overview of the use of poison primers in combination with target capture primers to achieve targeted depletion of non-target nucleic acid molecules from a nucleic acid library. In some embodiments, the non-target nucleic acid molecules are rRNA-derived cDNA molecules. [Figure 1B] Provides an overview of the use of poison primers in combination with target capture primers to achieve enrichment of target nucleic acid molecules from a next generation sequencing capture library by depleting the library of background molecules. In some embodiments, the target nucleic acid molecule is a fusion transcript. [Figure 2A] 1 shows an overview of a method for enriching target nucleic acid molecules in a prepared nucleic acid library according to one embodiment of the present disclosure. [Figure 2B] 1 illustrates a method for enriching target nucleic acid molecules in a prepared nucleic acid library according to one embodiment of the present disclosure. [Figure 2C] 1 illustrates a method of releasing a target nucleic acid molecule from a formed complex that includes at least a portion of the target nucleic acid molecule and an extended hybridized target capture primer, according to one embodiment of the present disclosure. [Figure 3A] According to one embodiment of the present disclosure, a method of primer extension target enrichment is shown in which hybridization and extension of a poison primer along a non-target nucleic acid molecule prevents or reduces the occurrence of mispriming of a target capture primer to a non-target nucleic acid. [Figure 3B] 1 illustrates an alternative method for capturing a target nucleic acid molecule utilizing a universal capture oligonucleotide. [Figure 4] 1 illustrates a method of primer extension target enrichment in which hybridization and extension of a poison primer along a non-target nucleic acid molecule cleaves the target capture moiety from a misprimed target capture primer, according to one embodiment of the present disclosure. [Diagram 5] 3B shows an alternative embodiment of the method shown in FIG. 3A, in which the target capture primer is attached to the substrate via a capture moiety prior to hybridization to the target nucleic acid molecule, according to one embodiment of the present disclosure. [Figure 6]6 shows an alternative embodiment of the method shown in FIG. 4, in which a target capture primer is bound to a substrate via a capture moiety prior to hybridization to a target nucleic acid molecule, according to one embodiment of the present disclosure. FIG. 6 further shows that a target capture primer bound to a substrate via a capture moiety can be misprimed to a non-target nucleic acid molecule, and the capture moiety bound to the substrate can be released by extension of a hybridized poison primer. [Figure 7] 1 illustrates a method of releasing an extended hybridized target capture primer from a target nucleic acid molecule prior to amplification and / or sequencing of the target nucleic acid molecule according to one embodiment of the present disclosure. [Figure 8] Shown are results from an experiment in which sgPETE averaged approximately 45% fewer rRNA reads in sequencing reads using 10 ng of UHR RNA as input to library preparation and capture. When 1 µM poison primer was included in the sgPETE capture reaction, the average number of rRNA reads was approximately 25% lower. In ribo-depleted samples, inclusion of poison primer did not result in a significant increase in off-target reads. [Figure 9A] The breakdown of sequencing reads subsampled to 3.5 million is shown, including 2.33 million (± 0.17 million) fusion target reads and 1.05 million (± 0.8 million) fusion reads in the control sample using poison primers. [Figure 9B] The theoretical sequencing depth and read breakdown required for control samples to detect a similar number of fusion targets is shown. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0030] Detailed Description It is also to be understood that, unless expressly stated to the contrary, in any method claimed herein that includes more than one step or act, the order of the method steps or acts is not necessarily limited to the order in which the method steps or acts are described.

[0031] definition

[0032] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly dictates otherwise. The term "comprising" is defined inclusively, such that "including A or B" means including A, B, or A and B.

[0033] As used herein and in the claims, "or" should be understood to have the same meaning as "and / or" as defined above. For example, when separating items in a list, "or" or "and / or" shall be interpreted as inclusive, e.g., including at least one of a number or list of elements, but including a plurality, and optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as "only one of" or "exactly one of," or, when used in the claims, "consisting of," refer to the inclusion of exactly one element of a number or list of elements. In general, the term "or" as used herein shall only be interpreted as indicating exclusive alternatives (e.g., "one or the other but not both") when preceded by terms of exclusivity, such as "either," "one of," "only one of," or "exactly one of." "Consisting essentially of," when used in the claims, shall have its ordinary meaning as used in the field of patent law.

[0034] Terms such as "comprising," "including," "having," and the like are used interchangeably and have the same meaning. Similarly, "comprises," "includes," "has," and the like are used interchangeably and have the same meaning. Specifically, each term is defined consistent with the general U.S. patent law definition of "comprising," and therefore is to be interpreted as an open term meaning "at least the following," and not to exclude additional features, limitations, aspects, and the like. Thus, for example, "a device having components a, b, and c" means that the device includes at least components a, b, and c. Similarly, the phrase: "a method including steps a, b, and c" means that the method includes at least steps a, b, and c. Additionally, although steps and processes may be outlined herein in a particular order, one of ordinary skill in the art will recognize that the ordering of steps and processes may vary.

[0035] As used herein in the specification and claims, the phrase "at least one" in connection with a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed in the list of elements, and not excluding any combination of elements in the list of elements. This definition also allows for elements other than those specifically identified in the list of elements to which the phrase "at least one" refers, may optionally be present, whether or not related to those elements specifically identified. Thus, as a non-limiting example, "at least one of A and B" (or, equivalently, "at least one of A or B," or, equivalently, "at least one of A and / or B") can refer in one embodiment to at least one, optionally more than one A, and no B (and optionally including elements other than B), in another embodiment to at least one, optionally more than one B, and no A (and optionally including elements other than A), in yet another embodiment to at least one, optionally more than one A, and at least one, optionally more than one B (and optionally including other elements), etc.

[0036] References throughout this specification to "one embodiment" or "an embodiment" mean that a particular feature, structure, or characteristic described in connection with an embodiment is included in at least one embodiment. Thus, the appearances of the phrase "in one embodiment" or "in an embodiment" in various places throughout this specification do not necessarily all refer to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0037] The term "adapter" refers to a nucleotide sequence that can be added to another sequence to confer additional properties to the sequence. Adapters can be single-stranded or double-stranded, or can have both single-stranded and double-stranded portions.

[0038] As used herein, "amplification" refers to a process in which copy number increases. Amplification can be a process in which replication occurs repeatedly over time to form multiple copies of a template. Amplification can result in an exponential or linear increase in copy number as amplification progresses. Exemplary amplification strategies include polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), rolling circle replication (RCA), cascade RCA, nucleic acid-based amplification (NASBA), and the like. Amplification can also utilize linear or circular templates. Amplification can be performed under any suitable temperature conditions, such as with thermal cycling or isothermal. Furthermore, amplification can be performed in an amplification mixture (or reagent mixture), which is any composition capable of amplifying a nucleic acid target, if there is one in the mixture. PCR amplification relies on repeated cycles of heating and cooling (i.e., thermal cycling) to achieve successive rounds of replication. PCR can be carried out by thermal cycling between two or more temperature set points, such as a higher denaturation temperature and a lower annealing / extension temperature, or between three or more temperature set points, such as a higher denaturation temperature, a lower annealing temperature, and an intermediate extension temperature, among others. PCR can be carried out using a thermostable polymerase, such as Taq DNA polymerase. PCR generally results in an exponential increase in the amount of product amplicon over successive cycles.

[0039] As used herein, the term "complementary" generally refers to the ability to form a precise pairing between two nucleotides. The term "complementary" refers to the ability to form favorable thermodynamic stability and specific pairing between the bases of two nucleotides at appropriate temperature and ionic buffer conditions. Complementarity is achieved by the differential interactions between the nucleobases of adenine, thymine (uracil in RNA), guanine and cytosine, where adenine pairs with thymine or uracil and guanine pairs with cytosine. For example, if a nucleotide at a given position of a nucleic acid can hydrogen bond with a nucleotide of another nucleic acid, the two nucleic acids are considered to be complementary to each other at that position. Complementarity between two single-stranded nucleic acid molecules may be "partial," where only a portion of the nucleotides bind, or may be complete, where there is total complementarity between the single-stranded molecules. A first nucleotide sequence can be said to be the "complement" of a second sequence if the first nucleotide sequence is complementary to the second nucleotide sequence. A first nucleotide sequence can be said to be the "reverse complement" of a second sequence if the first nucleotide sequence is complementary to a sequence that is the reverse of the second sequence (i.e., the order of nucleotides is reversed).

[0040] As used herein, the term "complementary DNA" or "cDNA" refers to DNA copied from RNA. In some embodiments, cDNA is DNA produced on an RNA template by the action of reverse transcriptase (RNA-dependent DNA polymerase). cDNA copied from mRNA does not contain various non-coding sequences characteristic of genomic DNA.

[0041] As used herein, the term "cDNA library" refers to a collection of cDNAs representing the messenger RNA expressed in a cell or tissue type.

[0042] As used herein, the term "conjugate" refers to two or more molecules (and / or materials, such as nanoparticles) that are covalently attached to a larger construct. In some embodiments, a conjugate comprises one or more other molecules, e.g., one or more biomolecules (such as peptides, proteins, enzymes, sugars, polysaccharides, lipids, glycoproteins, and lipoproteins) covalently attached to one or more other biomolecules.

[0043] As used herein, the term "enrichment" refers to a process that increases the relative abundance of a population of molecules, e.g., nucleic acid molecules, in a sample relative to the total amount of molecules initially present in the sample prior to processing. Thus, an enrichment step provides a percentage or fractional increase rather than a direct increase in the copy number of a nucleic acid sequence of interest, as does, for example, amplification methods such as the polymerase chain reaction.

[0044] As used herein, the term "fluid" refers to any liquid or liquid composition, including water, solvents, buffers, solutions (e.g., polar solvents, non-polar solvents), wash or cleaning fluids, and / or mixtures. Fluids may be aqueous or non-aqueous. In some embodiments, the wash fluid includes a surfactant to facilitate spreading of the wash fluid onto the specimen-bearing surface of the slide. In some embodiments, the acidic solution includes deionized water, an acid (e.g., acetic acid), and a solvent. In some embodiments, the alkaline solution includes deionized water, a base, and a solvent. In some embodiments, the transfer solution includes one or more glycol ethers, such as one or more propylene-based glycol ethers (e.g., propylene glycol ether, di(propylene glycol) ether, and tri(propylene glycol) ether), ethylene-based glycol ethers (e.g., ethylene glycol ether, di(ethylene glycol) ether, and tri(ethylene glycol) ether), and functional analogs thereof.

[0045] Non-limiting examples of buffering agents include citric acid, potassium dihydrogen phosphate, boric acid, diethylbarbituric acid, piperazine-N,N'-bis(2-ethanesulfonic acid), dimethylarsinic acid, 2-(N-morpholino)ethanesulfonic acid, tris(hydroxymethyl)methylamine (TRIS), 2-(N-morpholino)ethanesulfonic acid (TAPS), N,N-bis(2-hydroxyethyl)glycine (bicine), N-tris(hydroxymethyl)methylglycine (tricine), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid (TES), and combinations thereof. In other embodiments, the buffer may be comprised of tris(hydroxymethyl)methylamine (TRIS), 2-(N-morpholino)ethanesulfonic acid (TAPS), N,N-bis(2-hydroxyethyl)glycine (bicine), N-tris(hydroxymethyl)methylglycine (tricine), 4-2-hydroxyethyl-1-piperazineethanesulfonic acid (HEPES), 2-{[tris(hydroxymethyl)methyl]amino}ethanesulfonic acid (TES), or combinations thereof. Additional wash, transfer, acidic, and alkaline solutions are described in U.S. Patent Application Publication No. 2016 / 0282374, the disclosure of which is incorporated herein by reference in its entirety.

[0046] As used herein, the term "hybridize" refers to base pairing between different nucleic acid molecules that match their nucleotide sequences.

[0047] As used herein, the phrase "next-generation sequencing (NGS)" refers to sequencing technologies that have high-throughput sequencing compared to traditional Sanger and capillary electrophoresis-based approaches, where the sequencing process is performed in parallel, generating, for example, thousands or millions of relatively small sequence reads at a time. Some examples of next-generation sequencing technologies include, but are not limited to, sequencing-by-synthesis, sequencing-by-ligation, and sequencing-by-hybridization. These technologies generate shorter reads (anywhere from about 25 to about 500 bp), but generate hundreds of thousands or millions of reads in a relatively short time. The term "next-generation sequencing" refers to the so-called parallelized sequencing-by-synthesis or sequencing-by-ligation platforms currently employed by Illumina, Life Technologies, and Helicos Biosciences. Next generation sequencing methods can also include nanopore sequencing methods using electronic detection (Oxford Nanopore and Roche Diagnostics).

[0048] As used herein, the terms "nucleic acid" or "polynucleotide" (used interchangeably herein) refer to a polymeric form of nucleotides of any length, either deoxyribonucleotides or ribonucleotides, or analogs thereof. Polynucleotides may have any three-dimensional structure and may perform any function, known or unknown. Unless specifically limited, the term encompasses nucleic acids or polynucleotides that contain known analogs of natural nucleotides that have similar binding properties as the reference nucleic acid and are metabolized in a manner similar to naturally occurring nucleotides. Non-limiting examples of polynucleotides include coding or non-coding regions of a gene or gene fragment, locus(s) defined from phylogenetic analysis, exons, introns, messenger RNA (mRNA), transfer RNA, ribosomal RNA, ribozymes, cDNA, synthetic polynucleotides, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. Polynucleotides may include modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure may be imparted before or after assembly of the polymer. The sequence of nucleotides may be interrupted by non-nucleotide components. Polynucleotides may be further modified, such as by conjugation with a labeling component. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as the sequence explicitly indicated. Specifically, degenerate codon substitutions can be achieved by generating sequences in which the third position of one or more selected (or all) codons is substituted with mixed group and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0049] As used herein, the term "oligonucleotide" refers to an oligomer of nucleotide or nucleoside monomeric units, where the oligomer optionally contains non-nucleotide monomeric units and / or other chemical groups attached to internal and / or external positions of the oligomer. The oligomer may be natural or synthetic and may include naturally occurring oligonucleotides or oligomers containing nucleosides with non-naturally occurring (or modified) bases, sugar moieties, phosphodiester-analog linkages, and / or alternative monomeric unit chirality and isomeric structures (e.g., 5'- to 2'-linkages, L-nucleosides, α-anomeric nucleosides, β-anomeric nucleosides, locked nucleic acids (LNA), peptide nucleic acids (PNAs)).

[0050] As used herein, a "reaction" between any two different reactive groups (such as any two reactive groups of a reagent and a particle) can mean that a covalent bond is formed between the two reactive groups (or two reactive functional groups), or it can mean that the two reactive groups (or two reactive functional groups) associate with each other, interact with each other, hybridize with each other, hydrogen bond with each other, etc. In some embodiments, a "reaction" includes a binding event, e.g., a binding event between reactive functional groups or a binding event between a first and second member of a pair of specific binding entities.

[0051] As used herein, the term "polymerase" refers to an enzyme that performs template-directed synthesis of polynucleotides. DNA polymerases can only add free nucleotides to the 3' end of the newly formed strand. This causes the newly formed strand to extend in the 5'-3' direction. Known DNA polymerases cannot initiate new strands (de novo). DNA polymerases can only add nucleotides to existing 3'-OH groups and therefore require a primer to which the first nucleotide can be added. Non-limiting examples of polymerases include prokaryotic DNA polymerases (e.g., Pol I, Pol II, Pol III, Pol IV and Pol V), eukaryotic DNA polymerases, archaeal DNA polymerases, telomerases, reverse transcriptases and RNA polymerases. Reverse transcriptases are RNA-dependent DNA polymerases that synthesize DNA from an RNA template. The reverse transcriptase family includes both DNA polymerase functionality and RNaseH functionality that degrades RNA base-paired to DNA. RNA polymerase is an enzyme that synthesizes RNA using DNA as a template in the process of gene transcription. RNA polymerase polymerizes ribonucleotides at the 3' end of the RNA transcript.

[0052] In some embodiments, polymerases from the following can be used for polymerase-mediated primer extension, end modification (e.g., terminal transferase, degrade or polish) or amplification reactions: Archaea (e.g., Thermococcus litoralis (Vent, GenBank: AAA72101), Pyrococcus furiosus (Pfu, GenBank: D12983, BAA02362), Pyrococcus woesii, Pyrococcus GB-D (Deep Vent, GenBank: AAA67131), Thermococcus kodakaraensis KODI (KOD, GenBank: BD175553, BAA06142; Thermococcus sp. strain KOD (Pfx, GenBank: AAE68738)), Thermococcus gorgonarius (Tgo, Pdb: 4699806), Sulfolobus solataricus (GenBank:NC002754, P26811), Aeropyrum pernix (GenBank:BAA81109), Archaeglobus fulgidus (GenBank:029753), Pyrobaculum aerophilum (GenBank:AAL63952), Pyrodictium occultum (GenBank:BAA07579, BAA07580), Thermococcus 9 degree Nm (GenBank:AAA88769, Q56366), Thermococcus fumicolans (GenBank:CAA93738, P74918), Thermococcus hydrothermalis (GenBank:CAC18555), Thermococcus sp.GE8 (GenBank:CAC12850), Thermococcus sp.JDF-3 (GenBank:AX135456;WO0132887), Thermococcus sp.TY(GenBank:CAA73475)、Pyrococcus abyssi(GenBank:P77916)、Pyrococcus glycovorans(GenBank:CAC12849)、Pyrococcus horikoshii(GenBank:NP 143776)、Pyrococcus sp.GE23(GenBank:CAA90887)、Pyrococcus sp.ST700(GenBank:CAC 12847)、Thermococcus pacificus(GenBank:AX411312.1)、Thermococcus zilligii(GenBank:DQ3366890)、Thermococcus aggregans、Thermococcus barossii、Thermococcus celer(GenBank:DD259850.1)、Thermococcus profundus(GenBank:E14137)、Thermococcus siculi(GenBank:DD259857.1) Thermococcus thioreducens, Thermococcus onnurineus NA1, Sulfolobus acidocaldarium, Sulfolobus tokodaii, Pyrobaculum calidifontis, Pyrobaculum islandicum(GenBank:AAF27815), Methanococcus jannaschii (GenBank:Q58295) , Desulforococcus , TOK , Desulforococcus , Pyrolobus , Pyrodictium Staphylothermus, Vulcanisaetta, and Methanococcus (GenBank:P52025) are listed in the strain B. GenBank AAC62712, P956901, BAAA07579)) Manufacturer Thermus (flavus, ruber, thermophilus, lacteus, rubens, aquaticus), Bacillus stearothermophilus、Thermotoga maritima、Methanothermus fervidus、KODメメラー、TNA1ポメーー、Thermococcus sp.9 degrees N-7, T4, T7, phi29, Pyrococcus furiosus, P. abyssi, T. gorgonarius, T. litoralis, T. zilligii, T. sp. GT, P. sp. GB-D, CODE Pfu, T. gorgonarius, T. zilligii, T. litoralis, and Thermococcus sp.9N-7protein.

[0053] As used herein, the term "thermostable polymerase" refers to an enzyme that is heat stable, thermotolerant, and retains sufficient activity to subsequently carry out a polynucleotide extension reaction when exposed to high temperatures for the time required to carry out denaturation of double-stranded nucleic acid, and is not irreversibly denatured (inactivated). The heating conditions required for nucleic acid denaturation are known in the art and are exemplified, for example, in U.S. Pat. Nos. 4,683,202, 4,683,195, and 4,965,188, which are incorporated herein by reference. As used herein, a thermostable polymerase is suitable for use in temperature cycling reactions, such as polymerase chain reaction ("PCR"), primer extension reactions, or terminal modification (e.g., terminal transferase, degradation, or polishing) reactions. Irreversible denaturation for the purposes of this specification refers to the permanent and complete loss of enzyme activity. For thermostable polymerases, enzymatic activity refers to the catalysis of the combination of nucleotides in the appropriate manner to form polynucleotide extension products that are complementary to the template nucleic acid strand. Thermostable DNA polymerases from thermophilic bacteria include, for example, DNA polymerases from Thermotoga maritima, Thermus aquaticus, Thermus thermophilus, Thermus flavus, Thermus filiformis, Thermus sp. sp17, Thermus sp. Z05, Thermus caldophilus, Bacillus caldotenax, Thermotoga neopolitana, Thermosipho africanus, and other thermostable DNA polymerases disclosed above.

[0054] In some cases, the nucleic acid (e.g., DNA or RNA) polymerase can be a modified naturally occurring A-type polymerase. Further embodiments of the invention generally relate to methods in which the modified A-type polymerase, for example in primer extension, end modification (e.g., terminal transferase, degradation or polishing) or amplification reactions, can be selected from any species of the Meiothermus, Thermotoga or Thermomicrobium genera. Another embodiment of the invention generally relates to methods in which the polymerase, for example in primer extension, end modification (e.g., terminal transferase, degradation or polishing) or amplification reactions, can be isolated from any of Thermus aquaticus (Taq), Thermus thermophilus, Thermus caldophilus or Thermus filiformis. Further embodiments of the invention generally encompass methods in which a modified type A polymerase may be isolated from Bacillus stearothermophilus, Sphaerobacter thermophilus, Dictoglomus thermophilum, or Escherichia coli, for example in primer extension, end modification (e.g., terminal transferase, degradation, or polishing), or amplification reactions. In another embodiment, the invention generally relates to methods in which the modified type A polymerase may be a mutant Taq-E507K polymerase, for example in primer extension, end modification (e.g., terminal transferase, degradation, or polishing), or amplification reactions. Another embodiment of the invention generally relates to methods in which a thermostable polymerase may be used to perform amplification of a target nucleic acid.

[0055] As used herein, the term "primer" refers to an oligonucleotide that binds to a specific region of a single-stranded template nucleic acid molecule, extends from the 3' end of the primer, and initiates nucleic acid synthesis via a polymerase-mediated enzymatic reaction that is complementary to the sequence of the template molecule. PCR amplification primers can be referred to as "forward" and "reverse" primers, one of which is complementary to a nucleic acid strand and the other of which is complementary to the complement of that strand. Typically, primers contain less than about 100 nucleotides, and preferably less than about 30 nucleotides. Exemplary primers range from about 5 to about 25 nucleotides. Primers can contain, for example, RNA and / or DNA bases, as well as non-naturally occurring bases. The directionality of the newly formed strand (daughter strand) is opposite to the direction in which DNA polymerase moves along the template strand. In some cases, the target capture primer specifically hybridizes to the target polynucleotide under hybridization conditions. Such hybridization conditions may include, but are not limited to, hybridization in an isothermal amplification buffer (20 mM Tris-HCl, 10 mM (NH4)2SO4), 50 mM KCl, 2 mM MgSO4, 0.1% TWEEN® 20, pH 8.8, 25°C) at temperatures of about 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, or 70°C.

[0056] As used herein, the term "sequence", when used in reference to a nucleic acid molecule, refers to the order of nucleotides (or bases) in a nucleic acid molecule. When different species of nucleotides are present in a nucleic acid molecule, the sequence includes the identity of the species of nucleotide (or base) at each position in the nucleic acid molecule. A sequence is a property of all or a portion of a nucleic acid molecule. The term can similarly be used to describe the order and position identity of monomer units in other polymers, such as the amino acid monomer units of a protein polymer.

[0057] As used herein, the term "sequencing" refers to the determination of the order and position of bases in a nucleic acid molecule. More specifically, the term "sequencing" refers to a biochemical method for determining the order of nucleotide bases, adenine, guanine, cytosine and thymine, in a DNA oligonucleotide. Sequencing, as the term is used herein, can include, but is not limited to, parallel sequencing or any other sequencing method known to those skilled in the art, such as chain termination, rapid DNA sequencing, wandering-spot analysis, Maxam-Gilbert sequencing, dye terminator sequencing, or using any other modern automated DNA sequencing device.

[0058] As used herein, the term "substrate" refers to any material that can interact with a capture moiety. In some embodiments, the substrate is a solid support. In some embodiments, the solid support can include any type of solid, porous, or hollow sphere, ball, bearing, cylinder, capillary, channel, or other similar configuration of plastic, ceramic, metal, or polymeric material (e.g., hydrogel) to which nucleic acid molecules can be immobilized (e.g., covalently or non-covalently). In some embodiments, the solid support can include discrete particles that can be spherical (e.g., microspheres) or have non-spherical or irregular shapes, such as cubes, cuboids, pyramids, cylinders, cones, ovals, or disks. In some embodiments, the solid support can comprise a flat support such as a silica chip, microparticle, nanoparticle, plate, array, capillary, glass fiber filter, glass surface, metal surface (steel, gold silver, aluminum, silicon and copper), glass support, plastic support, silicon support, chip, filter, membrane, microwell plate, slide, multiwell plate or plastic material including membrane (e.g., formed from polyethylene, polypropylene, polyamide, polyvinylidene difluoride), and / or wafer, comb, pin or needle (e.g., an array of pins suitable for combinatorial synthesis or analysis), or beads in an array of pits or nanoliter wells on a flat surface such as a wafer (e.g., a silicon wafer), a wafer with pits with or without a filter bottom. In some embodiments, the solid support can be a solution phase support (e.g., glass beads, magnetic beads, or another similar particle) or a solid phase support (e.g., a silicon wafer, glass slide, etc.) that can be suspended in solution. Non-limiting examples of solution phase supports include superparamagnetic spherical polymer particles such as DYNABEADS magnetic beads manufactured by INVITROGEN, or magnetic glass particles as described in U.S. Pat. Nos. 656,568, 6,274,386, 7,371,830, 6,870,047, 6,255,477, 6,746,874, and 6,258,531, which are incorporated by reference in their entireties.

[0059] As used herein, the term "specific binding entity" refers to a member of a specific binding pair. A specific binding pair is a pair of molecules that are characterized by binding to one another to the substantial exclusion of binding to other molecules (e.g., a specific binding pair has a binding constant that is at least 10 times higher than the binding constant of either of the two members of the binding pair with other molecules in a biological sample). 3 M -1 Large, 10 4 M -1 Large or 10 5 M -1 (The specific binding moiety can have a large binding constant.) Examples of specific binding moieties include specific binding proteins (e.g., antibodies, lectins, avidins such as streptavidin, and protein A). Specific binding moieties can also include molecules (or portions thereof) that are specifically bound by such specific binding proteins.

[0060] As used herein, the term "substantially" refers to the qualitative condition of exhibiting the entire or nearly entire extent or degree of a characteristic or property of interest. In some embodiments, "substantially" means within about 5%. In some embodiments, "substantially" means within about 10%. In some embodiments, "substantially" means within about 15%. In some embodiments, "substantially" means within about 20%.

[0061] As used herein, the term "target" or "target sequence" refers to a nucleic acid molecule sequence of interest, e.g., a nucleic acid molecule sequence that hybridizes to an oligonucleotide probe.

[0062] As used herein, the term "universal primer" refers to a primer that can hybridize to and support the amplification of a target polynucleotide having a shared complementary universal primer binding site. Similarly, the term "universal primer pair" refers to a forward and reverse primer pair that can hybridize to and support the PCR amplification of a target polynucleotide having a shared complementary forward and reverse universal primer binding site. Such universal primer(s) and universal primer binding site(s) can enable single or dual primer mediated universal amplification of a target polynucleotide region of interest (e.g., universal PCR). The headings provided herein are for convenience only and do not interpret the scope or meaning of the disclosed embodiments.

[0063] overview

[0064] The present disclosure relates to compositions, kits, and methods for target enrichment by unidirectional primer extension, the compositions, kits, and methods utilizing both a poison primer and a target capture primer. One aspect of the present disclosure is a method for enriching a plurality of target nucleic acid molecules, for example, about 1 to about 10,000 target nucleic acid molecules, or about 1 to about 5,000 target nucleic acid molecules, or about 1 to about 1,000 target nucleic acid molecules, the method utilizing both a poison primer and a target capture primer.

[0065] The present disclosure also relates to a method of amplifying a target enriched sample, such as a target enriched sample prepared using any one of the methods described herein. In addition, the present disclosure also relates to a method of sequencing using a target enriched sample, such as a target enriched sample prepared using any one of the methods described herein. The method of the present disclosure can be used as part of a sequencing protocol, including a high-throughput single molecule sequencing protocol. In some embodiments, the method of the present disclosure generates a library of enriched target nucleic acid molecules to be sequenced. The enriched target nucleic acid molecules in the library can optionally incorporate barcodes for molecular identification and sample identification, as described in U.S. Patent Application Publication No. 2020 / 0032244, and U.S. Patent Nos. 7,393,665, 8,168,385, 8,481,292, 8,685,678 and 8,722,368, the disclosures of which are incorporated herein by reference in their entirety.

[0066] In some embodiments, the present disclosure describes a general approach for enrichment based on unidirectional dual probe primer extension that utilizes both a poison primer and a target capture primer. In some embodiments, the method includes hybridizing a first target capture primer to a first target nucleic acid molecule in a library of nucleic acid molecules, where the first target capture primer comprises a capture portion; hybridizing a first poison primer to a first non-target nucleic acid molecule in the library of nucleic acid molecules, where the first poison primer does not comprise a capture portion; and hybridizing the hybridized first poison primer to a first non-target nucleic acid molecule in the library of nucleic acid molecules, where the first poison primer does not comprise a capture portion. The method includes extending both the first target capture primer and the hybridized first poison primer, where the extension of the hybridized first target capture primer provides a first target capture primer extension complex comprising the first target nucleic acid molecule and the extended first target capture primer, and enriching the first target nucleic acid molecule in the library of nucleic acid molecules relative to the library of nucleic acid molecules. In some embodiments, the introduced poison primer hybridizes and extends to a non-target nucleic acid molecule ("non-target nucleic acid molecule") to prevent or reduce mispriming of the target capture primer with the non-target nucleic acid molecule. In other embodiments, the poison primer hybridizes upstream of the misprimed and hybridized target capture primer to the non-target nucleic acid molecule, and then extends and displaces the capture portion from the misprimed and hybridized target capture primer. It is believed that these two mechanisms of action may prevent or reduce downstream enrichment of misprimed non-target nucleic acid molecules.

[0067] Advantageously, the disclosed compositions, kits and methods allow enrichment of low abundance target nucleic acid molecules in a nucleic acid library that includes low abundance target nucleic acid molecules (e.g., mRNA; fusion transcripts) and high abundance non-target nucleic acid molecules (e.g., rRNA; wild-type transcripts). In some embodiments, poison primers are utilized to achieve targeted depletion of undesired molecules, i.e., non-target nucleic acid molecules, from next generation sequencing libraries. This may include rRNA-derived cDNA molecules and other non-target molecules that are undesirably captured and subsequently amplified downstream (see, e.g., FIG. 1A). Furthermore, in the context of cDNA libraries, the disclosed compositions, kits and methods facilitate enrichment of low abundance target molecules without the need for costly and time-consuming ribosome depletion steps. In other embodiments, poison primers are utilized to achieve enrichment of desired molecules from next generation sequencing capture libraries by depleting the library of background molecules. For example, this embodiment includes depletion of wild-type transcripts when searching for novel fusion transcripts (see, e.g., FIG. 1B).

[0068] Referring to FIG. 2A, in some embodiments, the methods disclosed herein include obtaining a nucleic acid library comprising a plurality of nucleic acid molecules (step 101). In some embodiments, the nucleic acid molecules in the obtained nucleic acid library are selected from DNA molecules, RNA molecules, genomic DNA molecules, cDNA molecules, mRNA molecules, rRNA molecules, mtDNA, siRNA molecules, or any combination thereof. In some embodiments, the plurality of nucleic acid molecules comprises single-stranded polynucleotides. In some embodiments, the plurality of nucleic acid molecules is derived from a tissue sample, such as a tissue sample from a mammalian subject. In other embodiments, the plurality of nucleic acid molecules is derived from a cytology sample, such as a cytology sample from a mammalian subject.

[0069] In some embodiments, the resulting nucleic acid library comprises a plurality of target nucleic acid molecules and / or a plurality of non-target nucleic acid molecules. In some embodiments, the non-target nucleic acid molecules are highly abundant relative to the target nucleic acid molecules in the nucleic acid library. In some embodiments, the non-target nucleic acid molecules represent at least about 70% of the nucleic acid molecules in the resulting nucleic acid library. In other embodiments, the non-target nucleic acid molecules represent at least about 75% of the nucleic acid molecules in the resulting nucleic acid library. In still other embodiments, the non-target nucleic acid molecules represent at least about 80% of the nucleic acid molecules in the resulting nucleic acid library. In further embodiments, the non-target nucleic acid molecules represent at least about 85% of the nucleic acid molecules in the resulting nucleic acid library. In still further embodiments, the non-target nucleic acid molecules represent at least about 90% of the nucleic acid molecules in the resulting nucleic acid library. In still further embodiments, the non-target nucleic acid molecules represent at least about 95% of the nucleic acid molecules in the resulting nucleic acid library. In some embodiments, the non-target nucleic acid molecules represent at least about 96% of the nucleic acid molecules in the resulting nucleic acid library. In some embodiments, the non-target nucleic acid molecules represent at least about 97% of the nucleic acid molecules in the resulting nucleic acid library. In some embodiments, the non-target nucleic acid molecules represent at least about 98% of the nucleic acid molecules in the resulting nucleic acid library. In some embodiments, the non-target nucleic acid molecules represent at least about 99% of the nucleic acid molecules in the resulting nucleic acid library.

[0070] In some embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 90% rRNA. In some embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 92% rRNA. In other embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 94% rRNA. In still other embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 95% rRNA. In further embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 96% rRNA. In further embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 97% rRNA. In further embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 98% rRNA. In further embodiments, the resulting nucleic acid library is a cDNA library comprising mRNA-derived molecules and at least about 99% rRNA. In some embodiments, the cDNA library comprises rRNA and mRNA derived molecules, and the cDNA library is derived from a biological sample that has not been previously treated with a ribosome depletion method, in some embodiments, it is desirable to enrich for mRNA derived molecules without having to perform a ribosome depletion step.

[0071] In some embodiments, the resulting nucleic acid library comprises fusion transcripts and wild-type transcripts. In some embodiments, the fusion transcripts are less abundant than the wild-type transcripts. In some embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:3. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:4. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:5. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:10. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:20. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:50. In other embodiments, the ratio of fusion transcripts to wild-type transcripts in the resulting nucleic acid library is at least about 1:100.

[0072] In some embodiments, the obtained nucleic acid library is derived from one or more tumor samples, and the target nucleic acid molecules include low abundance fusion transcripts. Non-limiting examples of fusion transcripts for detection include EML4-ALK, ETV6-NTRK3, and ALK-RET fusion oncogenes. In other embodiments, the obtained nucleic acid library includes expressed housekeeping genes, and the expressed housekeeping genes are low abundance compared to non-target nucleic acid molecules in the obtained nucleic acid library. Non-limiting examples of housekeeping genes include VCP, RAB7A, and CHMP2A.

[0073] In some embodiments, nucleic acid fragments are first prepared from a biological sample, such as a tissue sample and / or a cytology sample. A DNA sequencing library can be constructed from genomic DNA for genomic analysis, or from cDNA prepared from RNA or mRNA for transcriptomic analysis, and can be constructed from DNA or cDNA of any species from which these nucleic acids can be extracted. In some embodiments, the resulting sample is sheared into fragments to obtain a population of nucleic acid fragments. In some embodiments, shearing of the resulting genomic sample is accomplished using mechanical fragmentation (e.g., nebulization or sonication) and / or enzymatic fragmentation (e.g., restriction endonucleases). In some embodiments, the generated nucleic acid fragments are randomly sized. In some embodiments, the generated nucleic acid fragments have a length of less than about 1000 base pairs. In other embodiments, the generated nucleic acid fragments include sequence fragments having a sequence size ranging from about 100 to about 1000 base pairs in length. In yet other embodiments, the generated nucleic acid fragments include sequence fragments having a sequence size ranging from about 500 to about 750 base pairs in length.

[0074] In some embodiments, adapters are then added to the population of nucleic acid molecules via a ligation reaction. In some embodiments, the adapters comprise one or more barcode sequences. Methods for ligating adapters to nucleic acid molecules are described in U.S. Patent Application Publication Nos. 2017 / 0037459, 2018 / 0334709, 2018 / 0016630, and PCT Publication No. WO2017021449, the disclosures of which are incorporated herein by reference in their entirety.

[0075] Following fragmentation and preparation of the nucleic acid library (step 101), a primer pool is introduced into the nucleic acid library or into a reaction mixture containing the nucleic acid library and other components (e.g., buffers, etc.) to achieve hybridization. After their introduction, one or more poison primers and one or more target capture primers in the primer pool at least partially hybridize to one or more non-target and / or target nucleic acid molecules, respectively (steps 102 and 103).

[0076] In some embodiments, the primer pool comprises one or more poison primers and one or more target capture primers. In some embodiments, the primer pool comprises about 1 to about 1000 different poison primers. In some embodiments, the primer pool comprises about 50 to about 750 different poison primers. In other embodiments, the primer pool comprises about 100 to about 500 different poison primers. In some embodiments, the primer pool comprises about 50 to about 2500 different target capture primers. In other embodiments, the primer pool comprises about 150 to about 1000 different target capture primers.

[0077] In some embodiments, one or more target capture primers are target specific and thus designed to hybridize to a subset of complementary nucleic acid molecules (hereinafter referred to as "target nucleic acid molecules") within a nucleic acid library that contain the desired target genes, exons, and / or other genomic regions of interest. In some embodiments, the target capture primers comprise a pool of Roche SeqCap EZ Probes (available from Roche Sequencing and Life Sciences, Indianapolis, IND). In some embodiments, the target capture primers comprise a pool of Ampliseq primers available from ThermoFisher.

[0078] In some embodiments, the target capture primer may be comprised of ribonucleic acid, deoxyribonucleic acid, or other nucleic acid analogs known in the art. In some embodiments, the target capture primer may include one or more non-natural nucleotides, such as locked nucleic acid (LNA), peptide nucleic acid (PNA), gamma-PNA as glycol nucleic acid (GNA), and threose nucleic acid (TNA). In some embodiments, the target capture primer has a length ranging from about 20 nucleotides to about 100 nucleotides. In other embodiments, the target capture primer has a length ranging from about 40 nucleotides to about 80 nucleotides. In yet other embodiments, the target capture primer has a length ranging from about 50 nucleotides to about 75 nucleotides.

[0079] In some embodiments, each of the one or more target capture primers is a conjugate that includes (i) a capture moiety, (ii) a sequence that is substantially complementary to the sequence of one or more target nucleic acid molecules in the nucleic acid library. In some embodiments, each of the one or more target capture primers can be bound to a functionalized substrate via a capture moiety after hybridization and / or extension as described herein (see, for example, Figures 3A and 4). In other embodiments, the target capture primer is bound to a functionalized substrate via a capture moiety prior to hybridization as described herein (see, for example, Figures 5 and 6).

[0080] In some embodiments, each capture moiety of one or more target capture primers comprises a first moiety (e.g., a first reactive functional group) that is reactive with a second moiety (e.g., a second reactive functional group) of another entity (e.g., a second moiety conjugated to a functionalized substrate). In some embodiments, the first moiety is a first member of a pair of specific binding entities, and the second moiety is a second member of the same pair of specific binding entities. In some embodiments, "reaction" between a first moiety and a second moiety can mean that a covalent bond is formed between two reactive groups or two reactive functional groups of the two moieties, or that two reactive groups or two reactive functional groups of the two moieties associate with each other, interact with each other, hybridize with each other, hydrogen bond with each other, etc. Thus, in some embodiments, "reaction" includes a binding event, such as binding of a hapten to an anti-hapten antibody, or binding of biotin to streptavidin. In some embodiments, each of the target capture primers comprises the same capture moiety, e.g., biotin. In other embodiments, different subsets of target capture primers contain different capture moieties.

[0081] In some embodiments, the capture moiety may comprise biotin, which binds to a functionalized substrate comprising avidin or streptavidin. In other embodiments, the capture moiety may comprise a thiolated molecule, which binds to a functionalized substrate comprising a gold particle. In yet other embodiments, the capture moiety may comprise an amine-terminated molecule, which binds to an NHS-activated substrate.

[0082] In some embodiments, the capture moiety comprises an immobilized antibody that can be used to bind to a molecule that contains or is conjugated to a specific antigenic molecule, such as an antigenic molecule bound to a functionalized substrate. In other embodiments, the capture moiety comprises an antigenic molecule that can be used to bind to an immobilized antibody, such as an antibody bound to a functionalized substrate.

[0083] In some embodiments, the capture moiety comprises an enzyme that can be used to bind to a molecule that contains or is conjugated to a particular enzyme substrate, while in other embodiments, the capture moiety comprises a substrate for an enzyme that can be used to bind to an enzyme, such as an enzyme bound to a functionalized substrate.

[0084] In some embodiments, the capture moiety comprises a receptor that can be used to bind to a molecule that contains or is conjugated to a particular receptor ligand, such as a receptor ligand bound to a functionalized substrate, while in other embodiments, the capture moiety comprises one or more receptor ligands that can be used to bind to a molecule that contains a receptor, such as a receptor bound to a functionalized substrate.

[0085] In some embodiments, the capture moiety comprises a lectin that can be used to bind to a molecule that comprises or is conjugated to a particular polysaccharide, such as a polysaccharide bound to a functionalized substrate, while in other embodiments, the capture moiety comprises one or more polysaccharides that can be used to bind to a molecule that comprises or is conjugated to one or more lectins, such as one or more lectins bound to a functionalized substrate.

[0086] In still further embodiments, the capture moiety comprises one or more nucleic acid sequences that can be used to bind to molecules that contain or are conjugated to complementary base sequences. In other embodiments, the capture moiety can comprise a tethered DNA / RNA aptamer that can specifically bind to a target analyte, such as a small molecule, peptide, protein, cell, etc.

[0087] Each of the one or more poison primers is designed to hybridize to a second subset of complementary nucleic acid molecules (hereinafter referred to as "non-target nucleic acid molecules") in the nucleic acid library that do not contain the desired genes, exons, and / or other genomic regions of interest. Unlike the target capture primers, the poison primers of the present disclosure are not conjugated to any capture moiety and therefore cannot react with any functionalized substrate.

[0088] In some embodiments, the poison primer may be comprised of ribonucleic acid, deoxyribonucleic acid, or other nucleic acid analogs known in the art. In some embodiments, the poison primer may comprise one or more non-natural nucleotides, such as locked nucleic acid (LNA), peptide nucleic acid (PNA), gamma-PNA as glycol nucleic acid (GNA), and threose nucleic acid (TNA). In some embodiments, the poison primer has a length ranging from about 20 nucleotides to about 100 nucleotides. In other embodiments, the poison primer has a length ranging from about 40 nucleotides to about 80 nucleotides. In yet other embodiments, the poison primer has a length ranging from about 50 nucleotides to about 75 nucleotides.

[0089] In some embodiments, the poison primer has a lower melting temperature (T m In some embodiments, the poison primer has a T m is the T of the target capture primer m In another embodiment, the T of the poison primer is at least about 2% lower. m is the T of the target capture primer m In yet another embodiment, the T of the poison primer is at least about 5% lower. m is the T of the target capture primer m In a further embodiment, the T of the poison primer is at least about 10% lower than m is the T of the target capture primer m In yet a further embodiment, the T of the poison primer is at least about 15% lower than m is the T of the target capture primer m is at least about 20% lower.

[0090] In some embodiments, the first target capture primer has a melting temperature at least about 1° C. higher than the melting temperature of the first poison primer. In other embodiments, the first target capture primer has a melting temperature at least about 2° C. lower than the melting temperature of the first poison primer. In still other embodiments, the first target capture primer has a melting temperature at least about 3° C. higher than the melting temperature of the first poison primer. In further embodiments, the first target capture primer has a melting temperature at least about 4° C. higher than the melting temperature of the first poison primer. In still further embodiments, the first target capture primer has a melting temperature at least about 5° C. higher than the melting temperature of the first poison primer. In further embodiments, the first target capture primer has a melting temperature at least about 6° C. higher than the melting temperature of the first poison primer. In further embodiments, the first target capture primer has a melting temperature at least about 7° C. higher than the melting temperature of the first poison primer. In a further embodiment, the first target capture primer has a melting temperature at least about 8° C. higher than the melting temperature of the first poison primer. In a further embodiment, the first target capture primer has a melting temperature at least about 9° C. higher than the melting temperature of the first poison primer. In a further embodiment, the first target capture primer has a melting temperature at least about 10° C. higher than the melting temperature of the first poison primer.

[0091] In some embodiments, the T of the poison primer m is at least about 50° C. In some embodiments, the T m is at least about 55° C. In some embodiments, the T m is at least about 60° C. In some embodiments, the T m is at least about 65° C. In some embodiments, the T m is at least about 70° C. In some embodiments, the T m is at least about 75° C. In some embodiments, the Tm is at least about 80°C.

[0092] In some embodiments, the concentration of the target capture primer and the concentration of the poison primer are about the same. In other embodiments, the concentration of the target capture primer and the concentration of the poison primer are different. In some embodiments, the concentration of the poison primer is at least 2 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 5 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 10 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 20 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 50 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 100 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 200 times the concentration of the target capture primer. In other embodiments, the concentration of the poison primer is at least 500 times the concentration of the target capture primer. In some embodiments, one or more target capture primers may misprime, i.e., hybridize to a non-target nucleic acid molecule as opposed to a target nucleic acid molecule. A mispriming event is illustrated in FIG. 3A and FIG. 4-FIG. 6 herein. It is believed that the introduction, hybridization and / or extension of one or more poison primers prevents and / or mitigates the mispriming event. Furthermore, it is believed that if mispriming occurs, the extension of the hybridized poison primers may prevent and / or mitigate the subsequent capture and / or enrichment of the non-target nucleic acid molecule.

[0093] Following hybridization of the one or more target capture primers to one or more target nucleic acid molecules (step 102) and hybridization of the one or more poison primers to one or more non-target nucleic acid molecules (step 103), each of the one or more hybridized target capture primers and the one or more hybridized poison primers are extended (step 104) to form one or more extended target capture primer complexes and / or one or more extended poison primer complexes. If the target capture primer is misprimed, the misprimed hybridized target capture primer is extended along the non-target nucleic acid molecule, as further exemplified herein (see, e.g., FIG. 3A and FIG. 4-FIG. 6).

[0094] In some embodiments, one or more hybridized target capture primers are extended by use of a first polymerase, thus forming one or more double-stranded products, each of which comprises a target nucleic acid molecule hybridized to the extended target capture primer. In some embodiments, each of the one or more extended target capture primer complexes comprises an extended target capture primer (including a hybridized target capture primer that itself comprises a capture moiety) and a target nucleic acid sequence to which the target capture primer is hybridized. In some embodiments, the extended target capture primer comprises a reverse complement of at least a portion of the target nucleic acid molecule to which the target capture primer is hybridized.

[0095] If one or more target capture primers are misprimed, those misprimed target capture primers may also be extended using the first polymerase. In some embodiments, one or more misprimed hybridized target capture primers (hybridized to a non-target nucleic acid molecule) are extended by use of the first polymerase, thus forming one or more double-stranded products each comprising a non-target nucleic acid molecule hybridized to the extended target capture primer.

[0096] Similarly, one or more hybridized poison primers are extended by using a second polymerase, thus forming one or more double-stranded products, each of which comprises a non-target nucleic acid molecule hybridized to the extended poison primer. In some embodiments, each of the one or more extended poison primer complexes comprises an extended target capture primer and a non-target nucleic acid sequence hybridized to the poison primer. In some embodiments, the extended poison primer comprises at least a reverse complement of a portion of the non-target nucleic acid molecule hybridized to the poison primer.

[0097] In some embodiments, the first polymerase used to extend one or more hybridized target capture primers is the same as the second polymerase used to extend one or more hybridized poison primers. In other embodiments, the first polymerase used to extend one or more hybridized target capture primers is different from the second polymerase used to extend one or more hybridized poison primers. Depending on the type of nucleic acid molecule to be analyzed, the polymerase can be a DNA-dependent DNA polymerase ("DNA polymerase") or an RNA-dependent DNA polymerase ("reverse transcriptase"). Suitable polymerases are selected from Taq or Taq-derived polymerases (e.g., KAPA 2G polymerase from KAPA BIOSYSTEMS), or B-family DNA polymerases (e.g., KAPA HIFI polymerase from KAPA BIOSYSTEMS).

[0098] In some embodiments, the hybridization and extension processes (steps 102, 103, 104) are performed simultaneously. In other embodiments, the hybridization and extension processes (steps 102, 103, 104) are performed sequentially. In some embodiments, the extension length of the one or more hybridized target capture primers and the one or more hybridized poison primers can be controlled actively by techniques such as inactivating the added first and / or second polymerase, or passively by allowing the reaction to go to completion, such as by consumption of a limiting reactant. Such methods are further described in U.S. Patent Application Publication No. 2020 / 0032244, the disclosure of which is incorporated herein by reference in its entirety.

[0099] Referring again to Figure 2A, after extending both the hybridized target capture primer and the hybridized poison primer (step 104), the nucleic acid library is enriched for the presence of one or more target nucleic acid molecules. In some embodiments, enrichment involves increasing the concentration of the one or more target nucleic acid molecules by depletion (i.e., removal) of other members of the library of nucleic acid molecules that are not the target nucleic acid molecules. In some embodiments, enrichment involves forming one or more release primer extension complexes.

[0100] One method of target nucleic acid molecule enrichment is shown in Figure 2B. For example, in step 201, one or more target capture primer extension complexes are captured. Capture of one or more target capture primer extension complexes can be accomplished in a variety of ways as disclosed herein, and can be accomplished prior to, simultaneously with, or subsequent to any of the hybridization and / or extension steps described above.

[0101] In some embodiments, capturing includes contacting the target capture primer extension complexes with an appropriately functionalized substrate (e.g., beads) after the hybridization and / or extension steps, such that the capture moiety of each target capture primer extension complex reacts with the corresponding moiety of the functionalized substrate, thereby binding one or more target capture primer extension complexes to the functionalized substrate. For example, the target capture primer extension complexes may include a capture moiety that includes biotin that binds to a functionalized substrate that includes streptavidin. In embodiments in which the capture moiety is bound to a functionalized substrate (e.g., beads) prior to the hybridization step (i.e., prior to step 102), capture is achieved by hybridization of each target capture primer with its corresponding target nucleic acid. Other methods of capturing target capture primer extension complexes are described further herein and in U.S. Patent Application Publication No. 2020 / 0032244, the disclosure of which is incorporated herein by reference in its entirety.

[0102] In some embodiments, the functionalized substrate comprises beads having an appropriately functionalized surface (the substrate may be functionalized with any of the moieties described above). In some embodiments, the beads are contained within a column or a microfluidic device. In some embodiments, the beads are magnetic beads. In other embodiments, the beads are non-magnetic beads.

[0103] Following capture of the one or more target capture primer extension complexes, one or more purification processes are performed to remove non-target nucleic acid molecules as well as any other unused reaction components (e.g., nucleotides, primer molecules, enzymes, buffers, etc.) (step 202). For example, non-target nucleic acid molecules may be removed by flowing a wash fluid and / or buffer through a column containing a functionalized substrate (e.g., a column containing a plurality of beads having an appropriately functionalized surface). In some embodiments, washing is performed at least once. In other embodiments, washing is performed at least twice. In still other embodiments, washing is performed at least three times. One skilled in the art will appreciate that as the wash fluid and / or buffer flows through the column containing the functionalized substrate, the one or more target capture primer extension complexes bound to the functionalized substrate (e.g., beads) will remain bound to the functionalized substrate, while unbound non-target nucleic acid molecules will be washed away, resulting in a reaction mixture enriched for one or more target nucleic acid molecules.

[0104] In some embodiments, the target nucleic acid molecule can be optionally amplified after enrichment. In some embodiments, the captured target nucleic acid molecule is directly amplified while it is bound to the functionalized surface. Such methods are described in U.S. Patent Nos. 10,240,192, 10,160,995, and 7,842,457, the disclosures of which are incorporated herein by reference in their entirety. In other embodiments, one or more target nucleic acid molecules are released from the captured target capture primer extension complex (step 203) prior to the amplification step.

[0105] In some embodiments, the release of one or more target nucleic acid molecules follows the workflow shown in FIG. 2C. For example, in some embodiments, one or more release primers are hybridized to one or more target nucleic acid molecules (step 211). In some embodiments, one or more release primers are designed to hybridize to a portion of one or more target nucleic acid molecules and between the first adaptor and the second adaptor. In other embodiments, one or more release primers are designed to hybridize to a portion of the target nucleic acid molecule that is upstream relative to one or more target capture primer extension complexes. In some embodiments, the primer design algorithm is designed to choose a primer that is as close as possible to the capture primer. In some instances, there is no gap between the capture primer and the release primer. In some embodiments, the release primer does not have a capture portion, as does the poison primer. However, it has a similar Tm to the capture primer.

[0106] A polymerase is then used to extend the one or more hybridized release primers, thereby forming one or more extended hybridized release primers (step 212). In some embodiments, the extension of the one or more hybridized release primers by the polymerase liberates one or more target extension target capture primers from the one or more target capture primer extension complexes. In some cases, the polymerase exhibits strand displacement activity. In some cases, the polymerase exhibits 5'-3' exonuclease activity (referred to herein as 5'-3' double-stranded exonuclease activity) or double-stranded exonuclease activity that digests a single strand of a double-stranded nucleic acid molecule. In some cases, the polymerase exhibits both strand displacement and 5'-3' double-stranded exonuclease activity. In some cases, strand displacement, 5'-3' double-stranded exonuclease activity, or a combination thereof can displace a target nucleic acid molecule (e.g., the original target nucleic acid molecule from a provided sample) into solution.

[0107] For example, in some embodiments, the first double-stranded product containing the target nucleic acid molecule hybridized to the extended target capture primer is immobilized on a functionalized substrate, for example, by affinity capture of a ligand (e.g., biotin or a derivative thereof) via the capture portion of the extended target capture primer. In such embodiments, the strand displacement activity of the polymerase extending the hybridized release primer displaces the target nucleic acid molecule from the sample into solution. Alternatively, a 5'-3' exonuclease activity can degrade the extended target capture primer immobilized by affinity capture and hybridized to the target nucleic acid molecule, whereby the 5'-3' exonuclease activity releases the target nucleotide into solution. Further methods of releasing the target nucleic acid molecule from the formed target capture primer extension complex are described in U.S. Patent Application Publication No. 2018 / 0016630, which is incorporated herein by reference in its entirety.

[0108] The released target nucleic acid molecule or molecules can then be used in one or more downstream processes, such as sequencing, amplification, further coupling, etc. Referring again to FIG. 2A, in some embodiments, the nucleic acid library enriched for one or more target nucleic acid molecules is optionally amplified (step 106). In some embodiments, the optional amplification step (106) comprises one of linear amplification or exponential amplification (e.g., polymerase chain reaction (PCR)). As used herein, "PCR" refers to a reaction for the in vitro amplification of specific DNA sequences by simultaneous primer extension of complementary strands of DNA. As used herein, PCR encompasses derivative forms of the reaction, including, but not limited to, RT-PCR, real-time PCR, nested PCR, quantitative PCR, multiplexed PCR, digital PCR, digital droplet PCR, and assembly PCR. Amplification of the target nucleic acid molecules after enrichment can include non-PCR-based methods. Non-limiting examples of non-PCR based methods include nucleic acid sequence-based amplification (NASBA), transcription-mediated amplification (TMA), whole transcriptome amplification (WTA), whole genome amplification (WGA), multiple displacement amplification (MDA), strand displacement amplification (SDA), real-time SDA, rolling circle amplification, and / or circle-to-circle amplification.

[0109] Generally, amplification (step 106) involves amplifying the target nucleic acid molecule using a polymerase, a first amplification primer, and a second amplification primer. In some embodiments, the first and second amplification primers are designed to be complementary to the sequence of an adapter incorporated into one or more target nucleic acid molecules in the library of nucleic acid molecules in step 101. For example, the first amplification primer may have a 3' end that is complementary to the first adapter, and the second amplification primer may have a 3' end that is complementary to the second adapter. In some embodiments, the amplification primers may include any sequence present in the target nucleic acid molecule to be amplified (e.g., gene / target specific primers, universal primers, etc.) and can support the synthesis of one or both strands (i.e., both the top and bottom strands of a double-stranded nucleic acid molecule corresponding to the template for the amplification reaction). In some embodiments, the first and second amplification primers are universal primers. Further amplification methods are described in U.S. Patent Application Publication Nos. 2020 / 0032244 and 2018 / 0016630, the disclosures of which are incorporated by reference in their entireties.

[0110] In some embodiments, sequencing may be performed according to any method known to those skilled in the art (see step 107 in FIG. 2A). In some embodiments, sequencing methods include Sanger sequencing and dye terminator sequencing, as well as next-generation sequencing techniques such as pyrosequencing, nanopore sequencing, micropore-based sequencing, nanoball sequencing, MPSS, SOLiD, Illumina, Ion Torrent, Starlite, SMRT, tSMS, sequencing by synthesis, sequencing by ligation, mass spectrometry sequencing, polymerase sequencing, RNA polymerase (RNAP) sequencing, microscope-based sequencing, microfluidic Sanger sequencing, microscope-based sequencing, RNAP sequencing, etc. Sequencing devices and methods are disclosed, for example, in PCT Publication Nos. WO2014144478, WO2015058093, WO2014106076, and WO2013068528, the disclosures of which are incorporated by reference in their entireties.

[0111] In some embodiments, sequencing (step 107) can be performed by several different methods, such as using sequencing by synthesis technology. Prior art sequencing by synthesis is defined as any sequencing method that monitors the production of by-products upon incorporation of specific deoxynucleoside triphosphates during the sequencing reaction (Hyman, 1988, Anal. Biochem. 174:423-436; Rhonaghi et al., 1998, Science 281:363-365). One prominent embodiment of sequencing by synthesis reaction is pyrophosphate sequencing method. In this case, the production of pyrophosphate during nucleotide incorporation is monitored by an enzyme cascade that results in the production of a chemiluminescent signal. One example of sequencing by synthesis, the 454 Genome Sequencer System (Roche Applied Science Catalog No. 04 760 085 001), is based on pyrophosphate sequencing technology. When sequencing on a 454 GS20 or 454 FLX instrument, the average genomic DNA fragment size is in the range of 200 or 600 bp, respectively, as described in the product literature.

[0112] In some embodiments, the sequencing by synthesis reaction can alternatively be based on a terminator dye type sequencing reaction. In this case, the incorporated dye deoxynucleotriphosphate (ddNTP) building block contains a detectable label, which is preferably a fluorescent label that prevents further extension of the nascent DNA strand. The label is then removed and detected when the ddNTP building block is incorporated into the template / primer extension hybrid, for example by using a DNA polymerase that contains a 3'-5' exonuclease or proofreading activity.

[0113] In some embodiments, also in the case of genome sequencer workflow (Roche Applied Science catalogue 04 896 548 001), in the first step, (clonal) amplification is carried out by emulsion PCR. Therefore, it is also within the scope of the present disclosure that the step of amplification is carried out by emulsion PCR method. The beads carrying the clonally amplified target nucleic acid molecules can then be optionally transferred to a picotiter plate according to the manufacturer's protocol and subjected to pyrophosphate sequencing reaction for sequencing.

[0114] In some embodiments, sequencing is performed using next-generation sequencing methods, such as those provided by Illumina, Inc. ("Illumina Sequencing Method"). Without wishing to be bound by any particular theory, Illumina's next-generation sequencing technology uses clonal amplification and sequencing-by-synthesis (SBS) chemistry to enable rapid and accurate sequencing. This process simultaneously identifies DNA bases as they are incorporated into the nucleic acid strand. Each base emits a unique fluorescent signal when added to the growing strand, which is used to determine the order of the DNA sequence.

[0115] As noted above, it is desirable to prevent target capture primers from inadvertently "mispriming," i.e., binding to non-target sequences. The ability of poison primers to prevent or reduce "mispriming" from the outset is shown in a first non-limiting embodiment in FIG. 3A. The ability of poison primers to prevent or reduce capture of misprimed non-target molecules is shown in a second non-limiting embodiment in FIG. 4. In general, each of these two embodiments illustrates a method of primer extension target enrichment that involves in-solution primer-mediated capture of target nucleic acid molecules, followed by enrichment of the captured target nucleic acid molecules relative to other nucleic acid molecules present in a library of nucleic acid molecules.

[0116] FIG. 3A illustrates a method of target nucleic acid molecule enrichment in which an extended poison primer prevents or reduces the occurrence of mispriming of the target capture primer. In this embodiment, extension of the hybridized poison primer prevents the target capture primer from hybridizing to non-target nucleic acid molecules. Referring first to panel 301 of FIG. 3A, a library of nucleic acid molecules is first prepared, the library of nucleic acid molecules including one or more target nucleic acid molecules 323 and one or more non-target nucleic acid molecules 333. In some embodiments, the one or more target nucleic acid molecules 323 are low abundant relative to the one or more non-target nucleic acid molecules in the nucleic acid molecule library. For example, in some embodiments, the one or more target nucleic acid molecules may represent less than about 10% of the nucleic acid molecules in the nucleic acid molecule library. In other embodiments, the one or more target nucleic acid molecules may represent less than about 5% of the nucleic acid molecules in the nucleic acid molecule library. In some embodiments, adaptors (321, 322, 331, 332) are ligated to both ends of one or more target nucleic acid molecules 323 and one or more non-target nucleic acid molecules 333.

[0117] Panel 301 shows a target nucleic acid molecule 323, the target nucleic acid molecule having a first end including a first adaptor 301 and a second end including a second adaptor 322. Panel 301 further shows a non-target nucleic acid molecule 333, the non-target nucleic acid molecule having a first end including a first adaptor 331 and a second end including a second adaptor 333. The first adaptors 321 and 331 are located at the 5' ends of the target nucleic acid molecule and the non-target nucleic acid molecule, respectively. The second adaptors 322 and 332 are located at the 3' ends of the target nucleic acid molecule and the non-target nucleic acid molecule, respectively. In some embodiments, the first adaptors 321 and 331 are the same. Similarly, in some embodiments, the second adaptors 331 and 332 are the same.

[0118] After preparation of the nucleic acid library, one or more target capture primers 324 and one or more poison primers 334 are hybridized to the target nucleic acid molecules 323 and non-target nucleic acid molecules 333, respectively (see panel 302). In some embodiments, the one or more target capture primers 324 each include a target capture region 325 that is complementary to at least a portion of the target nucleic acid molecule 323, and a capture portion 326. The capture portion may include any of the moieties described above. In some embodiments, the capture portion is biotin. In some embodiments, the one or more poison primers 334 include a non-target specific region that is complementary to at least a portion of the non-target nucleic acid molecule 333. Notably, the one or more poison primers 334 do not include a capture portion and therefore cannot be captured during the enrichment step.

[0119] As shown in panel 303 of FIG. 3A, each of the one or more hybridized target capture primers and one or more poison primers are extended. In some embodiments, one or more hybridized target capture primers 324 are extended by a first polymerase (not shown), thereby generating one or more target capture primer extension complexes 328. Each of the one or more target capture primer extension complexes 328 includes a target nucleic acid molecule 323 and an extended target capture primer 327 (dashed lines indicate the extended portions of the hybridized target capture primers 324). As further shown in panel 303, one or more hybridized poison primers 334 are extended by a second polymerase (not shown), thereby generating one or more extended poison primers 335 (again, dashed lines indicate the extended portions of the hybridized poison primers 334).

[0120] One of skill in the art will appreciate that extension of the poison primer, in some embodiments, prevents or mitigates the target capture primer from mispriming to non-target strands (compare panel 303 of FIG. 3A with panels 402 and 403 of FIG. 4). In other words, formation of a double-stranded polynucleic acid prevents or mitigates the target capture primer from binding to non-target nucleic acid molecules, thus preventing or mitigating mispriming.

[0121] The target capture primer extension complex 328 is then captured onto a functionalized substrate 329 (see panel 304 of FIG. 3A). In some embodiments, the functionalized substrate comprises a solution phase support (e.g., a bead or another similar particle) or a solid phase support (e.g., a silicon wafer, a glass slide, etc.). Examples of magnetic glass particles and devices using same are described in U.S. Patent Nos. 656,568, 6,274,386, 7,371,830, 6,870,047, 6,255,477, 6,746,874, and 6,258,531, the disclosures of which are incorporated herein by reference in their entireties. In the embodiment shown in panel 304, the target capture primer extension complex 328 is captured onto a functionalized substrate 329 via a capture moiety 326. In some embodiments, the capture moiety 326 comprises biotin and the functionalized substrate comprises streptavidin. Alternative methods of target capture are described further herein (see, for example, the embodiment of FIG. 5).

[0122] In some embodiments, referring to Figure 3B, capture comprises hybridizing a universal capture oligonucleotide 351 to the target capture primer 324. In this particular embodiment, the target capture primer 324 comprises a portion that comprises a capture sequence, i.e., a universal nucleic acid sequence 350 (see panel 310). The introduced universal capture oligonucleotide 351 comprises a portion having a nucleic acid sequence that is complementary to the universal capture sequence 350 of the target capture primer 324, and further comprises a capture moiety 351. Similar to the embodiment shown in panel 304 of Figure 3A, capture further comprises introducing a functionalized substrate 329, which comprises a moiety that can react with or bind to the capture moiety 351.

[0123] After capture, the target capture primer extension complexes 328 are enriched for nucleic acid molecules present in the nucleic acid library. In some embodiments, enrichment includes removing nucleic acid molecules that are not captured on the functionalized substrate. In some embodiments, the non-captured nucleic acid molecules can be removed by running one or more wash solutions and / or buffer solutions through a column containing a solution-phase support. By comparing panels 301 and 305, one skilled in the art will understand that after capture of one or more target capture primer extension complexes and removal of non-captured nucleic acid molecules, the initial reaction mixture is enriched for one or more captured target nucleic acid molecules. In some embodiments, the captured target nucleic acid molecules are directly amplified while bound to the functionalized surface. In other embodiments, as further described herein (see FIG. 7), the target capture primer extension complexes 328 can be released from the functionalized substrate 329 so that the target nucleic acid molecules can be utilized in further downstream process operations (e.g., amplification and / or sequencing).

[0124] FIG. 4 illustrates a method of target nucleic acid enrichment in which an extended poison primer prevents capture of misprimed non-target nucleic acid molecules by a target capture primer. As described herein, extension of a poison primer hybridized to a non-target nucleic acid molecule cleaves the capture moiety from the formed target capture primer extension complex. Referring first to panel 401 of FIG. 4, a library of nucleic acid molecules is first prepared, the library of nucleic acid molecules including one or more target nucleic acid molecules 423 and one or more non-target nucleic acid molecules 433. In some embodiments, adaptors (421, 422, 431, 432) are ligated to both ends of the one or more target nucleic acid molecules 423 and one or more non-target nucleic acid molecules 433. In some embodiments, the one or more target nucleic acid molecules 423 are low abundant compared to the one or more non-target nucleic acid molecules in the nucleic acid molecule library. For example, in some embodiments, the one or more target nucleic acid molecules may represent less than about 10% of the nucleic acid molecules in the nucleic acid molecule library. In other embodiments, the one or more target nucleic acid molecules may represent less than about 5% of the nucleic acid molecules in the library of nucleic acid molecules. Panel 401 shows a target nucleic acid molecule 423, which includes a first end that includes a first adaptor 401 and a second end that includes a second adaptor 422.

[0125] Panel 401 further shows a non-target nucleic acid molecule 433, the non-target nucleic acid molecule comprising a first end including a first adaptor 431 and a second end including a second adaptor 433. The first adaptors 421 and 431 are located at the 5' ends of the target and non-target nucleic acid molecules, respectively. The second adaptors 422 and 432 are located at the 3' ends of the target and non-target nucleic acid molecules, respectively. In some embodiments, the first adaptors 421 and 431 are the same. Similarly, in some embodiments, the second adaptors 431 and 432 are the same.

[0126] After preparation of the nucleic acid library, one or more target capture primers 424 and one or more poison primers 434 are hybridized to the target nucleic acid molecules 423 and non-target nucleic acid molecules 433, respectively (see panel 402 of FIG. 4). In some embodiments, the one or more target capture primers 424 each include a target capture region 425 that is complementary to at least a portion of the target nucleic acid molecule 423 and a capture moiety 426 (e.g., biotin).

[0127] Also shown in panel 402 of Figure 4 is the mispriming of target capture primer 424 to a non-target nucleic acid molecule sequence 433. In other words, in some embodiments, target capture primer 424, including capture portion 426, can hybridize to a non-target nucleic acid molecule 433, i.e., the target capture primer is "misprimed." Thus, the non-target nucleic acid molecule can include both a hybridized poison primer and a hybridized misprimed target capture primer.

[0128] In some embodiments, one or more poison primers 434 include a non-target specific region that is complementary to at least a portion of a non-target nucleic acid molecule 433. Notably, one or more poison primers 434 do not include a capture moiety and therefore cannot be captured in downstream processes.

[0129] As shown in panel 403 of Figure 4, each of the one or more hybridized target capture primers, including those that are misprimed, and the one or more poison primers are extended. In some embodiments, one or more target capture primers 424 hybridized to a target nucleic acid molecule are extended by a first polymerase (not shown), thereby generating one or more target capture primer extension complexes 428. Each of the one or more target capture primer extension complexes 428 includes a target nucleic acid molecule 423 and an extended target capture primer 427 (dashed lines indicate the extended portion of the hybridized target capture primer 424). In some embodiments, target capture primers hybridized to non-target nucleic acid molecules are also extended by a first polymerase (not shown), thereby generating one or more misprimed extension complexes 430. As further shown in panel 403, one or more hybridized poison primers 434 are extended by a second polymerase (not shown) to generate one or more extended poison primers 435 (again, the dashed lines indicate the extended portions of the hybridized poison primers 434).

[0130] As the poison primer continues to extend, as further shown in panel 404 of Figure 4, the extended poison primer clips the capture moiety 426 from the target capture primer, thus releasing the capture moiety from the target capture primer extension complex. One of skill in the art will appreciate that extension of a hybridized poison primer prevents or reduces the occurrence of capture of non-target nucleic acid molecules.

[0131] The target capture primer extension complex 428 is then captured on a functionalized substrate 429 (see panel 405 of FIG. 4). In some embodiments, the functionalized substrate is a solution phase support (e.g., a bead or another similar particle) or a solid phase support (e.g., a silicon wafer, a glass slide, etc.). As mentioned above, any of the magnetic glass particles and devices using those described in U.S. Patent Nos. 656,568, 6,274,386, 7,371,830, 6,870,047, 6,255,477, 6,746,874, and 6,258,531 can be utilized. In the embodiment shown in panel 405, the target capture primer extension complex 428 is captured on a functionalized substrate 429 via a capture moiety 426. Alternative methods of target capture are described herein (see, for example, the embodiment of FIG. 6).

[0132] After capture, the target capture primer extension complexes 428 are enriched for nucleic acid molecules present in the nucleic acid library. In some embodiments, enrichment includes removing nucleic acid molecules that are not captured on the functionalized substrate, for example, the non-captured nucleic acid molecules can be removed by running one or more wash solutions and / or buffer solutions through a column containing a solution-phase support. By comparing panels 401 and 406, one skilled in the art will understand that after capture of one or more target capture primer extension complexes and removal of non-captured nucleic acid molecules, the initial reaction mixture is enriched for one or more captured target nucleic acid molecules. In some embodiments, the captured target nucleic acid molecules are directly amplified while bound to the functionalized surface. In other embodiments, as further described herein (see FIG. 7), the target capture primer extension complexes 428 can be released from the functionalized substrate 429 so that the target nucleic acid molecules can be utilized in further downstream process operations (e.g., amplification and / or sequencing).

[0133] As described herein, the capture portion of the target capture primer can be attached to a functionalized substrate prior to hybridization of the target capture primer to the target nucleic acid molecule. FIG. 5 shows an alternative workflow in which the target capture primer 324 is attached to a functionalized substrate 329 via a capture portion 326 prior to hybridization to the target nucleic acid molecule 323. In some embodiments, the target capture primer 324 attached to the functionalized substrate 329 hybridizes to the target nucleic acid molecule 323 (see panel 502). At the same time, the poison primer 334 hybridizes to the non-target nucleic acid molecule 333 (see panel 502). Similar to the embodiment shown in FIG. 3A, both the hybridized target capture primer 324 and the hybridized poison primer 334 are extended. In some embodiments, the extension of the poison primer prevents or reduces mispriming of the target capture primer to the non-target nucleic acid molecule 333. As shown in panel 503, the target capture primer extension complex 328 is bound to the functionalized substrate 329 via the capture moiety 326, so no separate capture step is required (compare panel 304 of FIG. 3A). In some embodiments, enrichment includes removing nucleic acid molecules that are not captured on the functionalized substrate, e.g., the uncaptured nucleic acid molecules may be removed by running one or more wash solutions and / or buffer solutions through a column containing the solution-phase support. As described further herein, the target capture primer extension complex 328 may be released from the functionalized substrate 329 such that the target nucleic acid molecule may be utilized in further downstream process operations (e.g., sequencing).

[0134] 6 illustrates another alternative workflow in which target capture primer 424 is attached to a functionalized substrate 429 via capture moiety 426 prior to hybridization to target nucleic acid molecule 423. In some embodiments, target capture primer 424 attached to functionalized substrate 429 hybridizes to target nucleic acid molecule 423 (see panel 602). At the same time, poison primer 434 hybridizes to non-target nucleic acid molecule 433 (see panel 502). Also illustrated in panel 602 is mispriming of target capture primer 424 (which is also attached to functionalized substrate 429 via capture moiety 426) to non-target nucleic acid molecule 433. Similar to the embodiment illustrated in FIG. 4, both hybridized target capture primer 424 and hybridized poison primer 434 are extended (see panel 603). As shown in panel 604 of Figure 6, as the poison primer 434 continues to extend, the extended poison primer clips the capture moiety 426 and the bound functionalized substrate 429 from the target capture primer, thus releasing the capture moiety from the target capture primer extension complex 428.

[0135] As shown in panel 604, the target capture primer extension complex 428 is bound to the functionalized substrate 429 via the capture moiety 426, so no separate capture step is required (compare panel 405 of FIG. 4). In some embodiments, enrichment includes removing nucleic acid molecules that are not captured on the functionalized substrate, e.g., the uncaptured nucleic acid molecules may be removed by running one or more wash solutions and / or buffer solutions through a column containing the solution-phase support. As described further herein, the target capture primer extension complex 428 may be released from the functionalized substrate 429 such that the target nucleic acid molecule may be utilized in further downstream process operations (e.g., sequencing).

[0136] As described above, in some embodiments, the target capture primer extension complex can be released from the functionalized substrate, so that the target nucleic acid molecule can be amplified and / or sequenced. Figure 7 shows a target capture prime extension complex 728 bound to a functionalized substrate 729 via a capture moiety 726 (see panel 701 of Figure 7). In some embodiments, a release primer 730 hybridizes to the target nucleic acid molecule 723 (see panel 702). In some embodiments, the release primer 730 is complementary to the target nucleic acid molecule 723 and hybridizes to the target nucleic acid molecule 723 at a 5' position relative to the target capture primer extension complex 728. As shown in panel 702, both the target capture primer extension complex 728 (attached to a functionalized substrate 729) and the release primer 730 hybridize to the target nucleic acid molecule 723.

[0137] 7, panel 703, the hybridized release primer 730 is extended by a third polymerase (not shown), thereby providing an extended release primer 731. In some embodiments, extension of the hybridized release primer 730 releases the extended target capture primer 727 from the target capture primer extension complex 728. In some embodiments, the extended target capture primer 727 remains attached to the solid support 218.

[0138] 2E, target nucleic acid molecule 723 is amplified by a fourth polymerase (not shown), a first amplification primer 735, and a second amplification primer 736. First amplification primer 735 includes a 3' end that is complementary to a first adaptor 721, and second amplification primer 736 includes a 3' end that is complementary to a second adaptor 722. In some embodiments, the first and second amplification primers are universal primers. EXAMPLES

[0139] Working Example Proof of principle was performed using Universal Human Reference UHR (Agilent) RNA as test material with 25 ng input mass. cDNA libraries were prepared using Kapa RNA HyperPrep. rRNA depleted libraries were prepared as a positive control using Kapa Ribo-Erase. Poison primers were designed against both strands of human rRNA-derived cDNA using reference GRCh38. The rRNA poison primers were designed with a T of 54°C to 58°C. m The set consisted of 98 primers (SEQ ID NOs: 1-98) designed in. All human rRNA genes were identified by searching the NCBI nucleotide archive (https: / / www.ncbi.nlm.nih.gov / nuccore) with the query "Homo sapiens'' [Organism] AND ''ribosomal rna'' [All Fields] AND biomol_rrna [PROP]". Nucleotide sequences were aligned using clustalW to examine sequence similarity. Based on sequence similarity, the list was reduced to representative rRNAs (Table 1). All possible putative primers of lengths between 16 and 31 bp were generated for the listed rRNA sequences. Primer sequences were aligned to the human reference genome GRCh38 using blat (https: / / github.com / dib-lab / ged-docs / wiki / BLAT). Putative primers were filtered for favorable PCR amplification properties based on the number of mapping positions and thermal melting temperature (>54 °C). Primers were selected to span each rRNA target on both the positive and negative strands with little or no overlap between primers. A poison primer was included in the capture reaction along with the capture primer. The target capture primers had an average T of 55°C. mThe capture primers consisted of 152 primers designed to detect known gene fusions with the nucleotide sequence ##STR1##. The target capture primers were accompanied by 152 primers ("release primers") designed to release the captured fragment from streptavidin in a subsequent release reaction. Input to the capture extension included a reaction with 1 μM poison primer and a reaction without poison primer as a control. The capture extension reaction contained: 1 μg cDNA, Kapa 2G multiplex mix (5×), 10 μL blocking oligo (37.3 μM), 2 μL Capture Primer Pool (1.64 nM / primer) and 2 μL poison primer pool (5 nM / primer), and 16 μL ddH2O. The capture extension reaction was performed using the following thermal cycle: 95° C. for 2 min, 80° C. for 1 s, 2% ramp to 60° C. in 10 min, 65° C. for 2 min, hold at 4° C. Extension products were captured by incubation with streptavidin magnetic beads in 1x binding buffer (100 mM NaCl, 10 mM Tris-HCl, 2% SDS). Beads were washed with wash buffer. Release primers were hybridized to the bead-captured targets for 30 min at 55°C. Release primer extension was performed for 2 min at 50°C using sgPETE release mix. The final release reaction was amplified using Kapa HiFi ReadyMix using 15 amplification cycles. Success of poison primer depletion was assessed by sequencing on an Illumina Nextseq 500 using a 2x150bp read workflow. The number of demultiplexed reads for each sample ranged from 3.98 million to 10.1 million. For bioinformatics analysis, the number of reads used for all samples was subsampled to 3.5 million reads. Quality filtered sequencing reads filtered using fastp were de-duplicated using the UMI tool using default settings. Sequencing reads mapping to rRNA reads were mapped using BWM MEM. Remaining non-rRNA reads were mapped to the RNA reverence Hg38 using the STAR aligner.Referring to FIG. 8, the UHR control samples had cDNA without rRNA depletion as input and no poison primer was added to the capture reaction. The UHR no RiboErase 1 μM samples had cDNA without rRNA depletion as input and contained 1 μM poison primer in the capture reaction. Samples containing poison primer showed a reduction in the abundance of off-target rRNA fragments being sequenced, averaging 19.47% (± 4.17%) compared to control samples, which averaged 44.83% (± 1.97%). The number of desired targets also increased when poison primer was included in the capture reaction. In a subsample of 3.5 million reads, 2.33 million (± 170,000) fusion target reads were detected when poison primer was included, compared to 1.05 million (± 80,000) sequencing reads in the control sample (FIG. 9A). Thus, the inclusion of the poison primer resulted in a higher read depth for the fusion target, even with the same overall sequencing depth. In this example, the control sample would theoretically require 7.71 million reads to reach the same fusion target read depth as the poison primer treatment (Figure 9B). The % of off-target unmapped reads was not significantly different between the Ribo-Erase treated sample and the Ribo-Erase treated sample with the poison primer. Thus, the inclusion of the poison primer did not adversely affect the sequencing metrics as observed for the Ribo-Erase treated sample (Figure 8).

[0140] All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to herein and / or listed in the Application Data Sheet are incorporated herein by reference in their entirety. Aspects of the embodiments can be modified, if necessary, to use concepts from the various patents, applications, and publications to provide further embodiments.

[0141] Although the present disclosure has been described with reference to certain exemplary embodiments, it should be understood that numerous other modifications and embodiments may be devised by those skilled in the art that would fall within the spirit and scope of the principles of the present disclosure. More specifically, reasonable variations and modifications are possible in the components and / or arrangements of the combined configuration of the subject matter within the scope of the foregoing disclosure, the drawings, and the appended claims without departing from the spirit of the present disclosure. In addition to modifications and changes in the components and / or arrangements, alternative uses will also be apparent to those skilled in the art.

Claims

1. 1. A method for enriching at least one target nucleic acid molecule in a library of nucleic acid molecules, comprising: (a) hybridizing a first target capture primer to a first target nucleic acid molecule in the library of nucleic acid molecules, wherein the first target capture primer comprises a capture moiety; (b) hybridizing a first poison primer to a first non-target nucleic acid molecule in the library of nucleic acid molecules, wherein the first poison primer does not include a capture moiety; (c) extending both the hybridized first target capture primer and the hybridized first poison primer, wherein the extension of the hybridized first target capture primer provides a first target capture primer extension complex comprising the first target nucleic acid molecule and the extended first target capture primer; and (d) enriching the first target nucleic acid molecule in the library of nucleic acid molecules relative to the library of nucleic acid molecules; Including, wherein the first poison primer comprises a sequence complementary to the first non-target nucleic acid molecule, the Tm of the first poison primer is between 50°C and 68°C, the Tm of the first target capture primer is at least 1°C higher than the Tm of the first poison primer, and the concentration of the first poison primer is the same as or at least twice as high as the concentration of the first target capture primer. The method.

2. 2. The method of claim 1, wherein the first target capture primer and the first poison primer are added to the library as a pool of primers.

3. 3. The method of claim 1 or 2, wherein the extension of the hybridized first poison primer prevents the first target capture primer from hybridizing to the first non-target nucleic acid molecule.

4. 3. The method of claim 1 or 2, wherein the extension of the hybridized first poison primer displaces a first target primer hybridized to the first non-target nucleic acid molecule.

5. 5. The method of any one of claims 1 to 4, wherein each of the nucleic acid molecules in the library of nucleic acid molecules comprises a first end comprising a first adaptor and a second end comprising a second adaptor.

6. 6. The method of claim 5, further comprising amplifying the first target nucleic acid molecule with a first amplification primer and a second amplification primer, wherein the first amplification primer comprises a 3' end that is complementary to the first adapter and the second amplification primer comprises a 3' end that is complementary to the second adapter.

7. 7. The method of any one of claims 1 to 6, wherein enriching the first target nucleic acid molecule for the library of nucleic acid molecules comprises: (i) capturing the first target capture primer extension complex; (i) removing uncaptured non-target nucleic acid molecules; and (ii) releasing the first target nucleic acid molecule from the captured first target capture primer extension complex.

8. 8. The method of claim 7, wherein the capturing of the first target capture primer extension complex comprises contacting the first target capture primer extension complex with a functionalized substrate.

9. 8. The method of claim 7, wherein the capturing of the first target capture primer extension complex comprises: (i) hybridizing a universal capture oligonucleotide to the capture portion of the first target capture primer extension complex to form a universal capture oligonucleotide complex, where the universal capture oligonucleotide comprises (a) a first member of a pair of specific binding entities and (b) a nucleotide sequence complementary to at least a portion of the capture sequence of the capture portion; and (ii) contacting the universal capture oligonucleotide complex with a functionalized substrate, where the functionalized substrate comprises a second member of the pair of specific binding entities.

10. 10. The method of any one of claims 7 to 9, wherein the removing of the non-captured non-target nucleic acid molecules comprises washing away the non-captured non-target nucleic acid molecules.

11. the releasing of the captured first target capture primer extension complex comprises: (i) hybridizing a release primer to the first target nucleic acid molecule; and (b) extending the hybridized release primer; wherein the release primer hybridizes to a portion of the first target nucleic acid molecule, and the Tm of the release primer is the same as that of the first poison primer. m having The method according to any one of claims 7 to 10.

12. The method of any one of claims 1 to 11, wherein the first target capture primer has a melting temperature higher than the melting temperature of the first poison primer.

13. 13. The method of any one of claims 1 to 12, wherein the library of nucleic acid molecules comprises a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules, wherein the plurality of target nucleic acid molecules are in low abundance compared to the plurality of non-target nucleic acid molecules.

14. (a) a first target capture primer that is complementary to a target nucleic acid molecule in a library of nucleic acid molecules and comprises a capture moiety; (b) a first poison primer that is complementary to a non-target nucleic acid molecule in the library of nucleic acid molecules and does not contain a capture moiety; A kit comprising: wherein the first poison primer comprises a sequence complementary to the non-target nucleic acid molecule, the Tm of the first poison primer is between 50°C and 68°C, the Tm of the first target capture primer is at least 1°C higher than the Tm of the first poison primer, and the concentration of the first poison primer is the same as or at least twice as high as the concentration of the first target capture primer. The kit.

15. (a) a nucleic acid library comprising a plurality of target nucleic acid molecules and a plurality of non-target nucleic acid molecules, wherein the target nucleic acid molecules are in low abundance relative to the plurality of non-target nucleic acid molecules; (b) a first target capture primer that is complementary to a first target nucleic acid molecule in the library of nucleic acid molecules and comprises a capture moiety; (c) a first poison primer that is complementary to a first non-target nucleic acid molecule in the library of nucleic acid molecules and does not contain a capture moiety; and (d) a first polymerase; A composition comprising: wherein the first poison primer comprises a sequence complementary to the first non-target nucleic acid molecule, the Tm of the first poison primer is between 50°C and 68°C, the Tm of the first target capture primer is at least 1°C higher than the Tm of the first poison primer, and the concentration of the first poison primer is the same as or at least twice as high as the concentration of the first target capture primer. The composition.

16. The method of any one of claims 1 to 13, wherein the first non-target nucleic acid molecule is rRNA or a rRNA-derived cDNA molecule.

17. The kit of claim 14, wherein the non-target nucleic acid molecule is rRNA or an rRNA-derived cDNA molecule.

18. The composition of claim 15, wherein the first non-target nucleic acid molecule is rRNA or an rRNA-derived cDNA molecule.

Citation Information

Patent Citations

  • Method for detecting gene using competing oligonucleotide

    JP2008161165A

  • Method for eliminating influence of impurity

    JP2011087534A

  • Target sequence enrichment

    JP2016515384A

  • Method for selectively amplifying DNA of target bacterium in bacterial population

    JP2020191833A

  • Target enrichment by unidirectional dual probe primer extension

    WO2019121842A1